ULK1
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
Log-Odds: S Sites / S Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A2RUS2 | S472 | SIGNOR|EPSD|PSP | DENND3 KIAA0870 | EKRASRKSSHLHVTHRRMVVsMPNLQDIAMPELAPRNssLR |
| A2RUS2 | S490 | SIGNOR|EPSD|PSP | DENND3 KIAA0870 | VVsMPNLQDIAMPELAPRNssLRLTDTAGCRGssAVLNVtP |
| O00560 | S6 | EPSD|PSP | SDCBP MDA9 SYCL | _______________MsLyPsLEDLKVDKVIQAQTAFSANP |
| O00560 | S60 | PSP | SDCBP MDA9 SYCL | PHDGNLyPRLyPELsQyMGLsLNEEEIRANVAVVsGAPLQG |
| O15027 | S846 | PSP | SEC16A KIAA0310 SEC16 SEC16L | PPVLIAQPDHSYNLAQPINFsVSLSNSHEKNQSWREALVGD |
| O60238 | S35 | PSP | BNIP3L BNIP3A BNIP3H NIX | NNNNCEENEQSLPPPAGLNssWVELPMNSSNGNDNGNGKNG |
| O60260 | S108 | GPS6|PSP | PRKN PARK2 | PRNAAGGCEREPQsLTRVDLsssVLPGDSVGLAVILHTDsR |
| O75143 | S355 | EPSD|PSP | ATG13 KIAA0652 | DRTHCAAtPSSSEDTEtVsNssEGRAsPHDVLETIFVRKVG |
| O75143 | S389 | PSP | ATG13 KIAA0652 | IFVRKVGAFVNKPINQVTLTsLDIPFAMFAPKNLELEDTDP |
| O75385 | S317 | PSP | ULK1 KIAA0722 | ssGSGSSSSSSSTSHLASPPsLGEMQQLQKTLAsPADTAGF |
| P06733 | S115 | SIGNOR|EPSD|PSP | ENO1 ENO1L1 MBPB1 MPB1 | IEMDGtENKsKFGANAILGVsLAVCKAGAVEKGVPLyRHIA |
| P06733 | S282 | SIGNOR|EPSD|PSP | ENO1 ENO1L1 MBPB1 MPB1 | KsPDDPsRyIsPDQLADLyKsFIKDyPVVsIEDPFDQDDWG |
| P08235 | S843 | PSP | NR3C2 MCR MLR | NSQFLYFAPDLVFNEEKMHQsAMYELCQGMHQISLQFVRLQ |
| P08237 | S74 | SIGNOR|EPSD|PSP | PFKM PFKX | GYQGLVDGGDHIKEATWESVsMMLQLGGTVIGSARCKDFRE |
| P08237 | S762 | SIGNOR|EPSD|PSP | PFKM PFKX | WLKLRPILKILAKYEIDLDTsDHAHLEHITRKRSGEAAV__ |
| P09467 | S63 | SIGNOR|EPSD|PSP | FBP1 FBP | KAISSAVRKAGIAHLYGIAGsTNVTGDQVKKLDVLSNDLVM |
| P09467 | S88 | SIGNOR|EPSD|PSP | FBP1 FBP | GDQVKKLDVLSNDLVMNMLKsSFATCVLVSEEDKHAIIVEP |
| P19367 | S124 | SIGNOR|EPSD|PSP | HK1 | NVHMESEVYDTPENIVHGSGsQLFDHVAECLGDFMEKRKIK |
| P19367 | S364 | SIGNOR|EPSD|PSP | HK1 | KNKEGLHNAKEILTRLGVEPsDDDCVSVQHVCTIVSFRSAN |
| P46937 | S227 | SIGNOR|PSP | YAP1 YAP65 | LSQMNVTAPTsPPVQQNMMNsASGPLPDGWEQAMTQDGEIY |
| P58004 | S254 | PSP | SESN2 Hi95 SEST2 | PSEQSSPPSRDPLNNsGGFEsARDVEALMERMQQLQESLLR |
| P58004 | S73 | PSP | SESN2 Hi95 SEST2 | VLREGAESLEQHLGLEALMSsGRVDNLAVVMGLHPDYFTSF |
| Q12983 | S17 | PSP | BNIP3 NIP3 | ____MSQNGAPGMQEESLQGsWVELHFsNNGNGGSVPAsVS |
| Q12983 | S35 | GPS6 | BNIP3 NIP3 | QGsWVELHFsNNGNGGSVPAsVSIYNGDMEKILLDAQHESG |
| Q13045 | S64 | PSP | FLII FLIL | GLCYLPEELAALQKLEHLSVsHNNLTTLHGELSSLPSLRAI |
| Q13546 | S262 | PSP | RIPK1 RIP RIP1 | KSGNRPDVDDITEYCPREIIsLMKLCWEANPEARPTFPGIE |
| Q13546 | S291 | PSP | RIPK1 RIP RIP1 | NPEARPTFPGIEEKFRPFYLsQLEEsVEEDVKSLKKEYSNE |
| Q13546 | S296 | PSP | RIPK1 RIP RIP1 | PTFPGIEEKFRPFYLsQLEEsVEEDVKSLKKEYSNENAVVK |
| Q13546 | S320 | PSP | RIPK1 RIP RIP1 | DVKSLKKEYSNENAVVKRMQsLQLDCVAVPssRsNsAtEQP |
| Q13546 | S333 | PSP | RIPK1 RIP RIP1 | AVVKRMQsLQLDCVAVPssRsNsAtEQPGSLHssQGLGMGP |
| Q13546 | S335 | PSP | RIPK1 RIP RIP1 | VKRMQsLQLDCVAVPssRsNsAtEQPGSLHssQGLGMGPVE |
| Q13546 | S345 | PSP | RIPK1 RIP RIP1 | CVAVPssRsNsAtEQPGSLHssQGLGMGPVEEsWFAPSLEH |
| Q13546 | S346 | PSP | RIPK1 RIP RIP1 | VAVPssRsNsAtEQPGSLHssQGLGMGPVEEsWFAPSLEHP |
| Q13546 | S357 | PSP | RIPK1 RIP RIP1 | tEQPGSLHssQGLGMGPVEEsWFAPSLEHPQEENEPSLQSK |
| Q13546 | S389 | PSP | RIPK1 RIP RIP1 | ENEPSLQSKLQDEANyHLyGsRMDRQTKQQPRQNVAYNREE |
| Q13546 | T337 | PSP | RIPK1 RIP RIP1 | RMQsLQLDCVAVPssRsNsAtEQPGSLHssQGLGMGPVEEs |
| Q14457 | S15 | PSP | BECN1 GT197 | ______MEGSKTSNNSTMQVsFVCQRCSQPLKLDTsFKILD |
| Q14457 | S279 | PSP | BECN1 GT197 | TQLDKLKKTNVFNATFHIWHsGQFGTINNFRLGRLPsVPVE |
| Q14457 | S30 | PSP | BECN1 GT197 | STMQVsFVCQRCSQPLKLDTsFKILDRVTIQELTAPLLTTA |
| Q14457 | S337 | PSP | BECN1 GT197 | LANKMGLKFQRYRLVPyGNHsYLESLTDKSKELPLyCSGGL |
| Q14457 | S96 | PSP | BECN1 GT197 | DGVSRRFIPPARMMsTEsANsFTLIGEASDGGtMENLSRRL |
| Q15436 | S207 | EPSD|PSP | SEC23A | YVFRGTKDLSAKQLQEMLGLsKVPLTQATRGPQVQQPPPSN |
| Q15436 | T405 | EPSD|PSP | SEC23A | TFQRVFTKDMHGQFKMGFGGtLEIKTSREIKISGAIGPCVS |
| Q15437 | S186 | SIGNOR|PSP | SEC23B | LITFGRMVQVHELSCEGISKsYVFRGTKDLTAKQIQDMLGL |
| Q16543 | S339 | EPSD|PSP | CDC37 CDC37A | DAISKMDPTDAKYHMQRCIDsGLWVPNSKASEAKEGEEAGP |
| Q676U5 | S278 | PSP | ATG16L1 APG16L UNQ9393/PRO34307 | RAISRAATKRLsQPAGGLLDsITNIFGRRsVssFPVPQDNV |
| Q6ZNE5 | S29 | PSP | ATG14 ATG14L KIAA0831 | ARALEAPGCGPRPLARDLVDsVDDAEGLYVAVERCPLCNTT |
| Q7Z3C6 | S14 | SIGNOR|EPSD|PSP | ATG9A APG9L1 | _______MAQFDTEyQRLEAsysDsPPGEEDLLVHVAEGSK |
| Q7Z3C6 | S761 | SIGNOR|EPSD|PSP | ATG9A APG9L1 | sAPDEGGEGARAPQSIPRsAsYPCAAPRPGAPETTALHGGF |
| Q86WV6 | S366 | EPSD|PSP | STING1 ERIS MITA STING TMEM173 | LKTSAVPSTsTMsQEPELLIsGMEKPLPLRTDFS_______ |
| Q8IVP5 | S17 | SIGNOR|PSP | FUNDC1 | ____MATRNPPPQDyEsDDDsyEVLDLTEYARRHQWWNRVF |
| Q8N122 | S792 | EPSD|PSP | RPTOR KIAA1303 RAPTOR | PENEEHILSFETIDKMRRAssYSSLNSLIGVSFNSVYTQIW |
| Q8N122 | S855 | EPSD|PSP | RPTOR KIAA1303 RAPTOR | NSIAYKATVNARPQRVLDtssLtQsAPAsPtNKGVHIHQAG |
| Q8N122 | S859 | EPSD|PSP | RPTOR KIAA1303 RAPTOR | YKATVNARPQRVLDtssLtQsAPAsPtNKGVHIHQAGGsPP |
| Q8N122 | S863 | PSP | RPTOR KIAA1303 RAPTOR | VNARPQRVLDtssLtQsAPAsPtNKGVHIHQAGGsPPAsst |
| Q8N122 | S877 | PSP | RPTOR KIAA1303 RAPTOR | tQsAPAsPtNKGVHIHQAGGsPPAsstssssLtNDVAKQPV |
| Q8NEB9 | S249 | PSP | PIK3C3 VPS34 | KEyGIVYYEKDGDEssPILTsFELVKVPDPQMSMENLVESK |
| Q8NFG4 | S406 | PSP | FLCN BHD | SAFEVLRTMLPVGCVRIIPYsSQYEEAYRCNFLGLSPHVQI |
| Q8NFG4 | S537 | PSP | FLCN BHD | VLFKFTKVDSRPKEDTQKLLsILGAsEEDNVKLLKFWMTGL |
| Q8NFG4 | S542 | PSP | FLCN BHD | TKVDSRPKEDTQKLLsILGAsEEDNVKLLKFWMTGLSKTYK |
| Q8TDY2 | S1323 | PSP | RB1CC1 KIAA0203 RBICC | LEQLEEQEKRKNEEMQNVRTsLIAEQQTNFNTVLTREKMRK |
| Q8TDY2 | S943 | PSP | RB1CC1 KIAA0203 RBICC | VICLQNEKDQKLLEMENIMHsQNCEIKELKQSREIVLEDLK |
| Q8TDY2 | S986 | PSP | RB1CC1 KIAA0203 RBICC | HVENDEKLQLLRAELQsLEQsHLKELEDTLQVRHIQEFEKV |
| Q8TEV9 | S400 | EPSD|PSP | SMCR8 | DRMVEKQESIPSKPsQDRPPsssLEECPIPKVLIsVGsYKS |
| Q8TEV9 | S492 | EPSD|PSP | SMCR8 | IEVLGTEKSTSVLsKsDsQAsLtVPLsPQVVRSKAVSHRtI |
| Q8TEV9 | S562 | EPSD|PSP | SMCR8 | NEEESYPDGNEGAIRFQASIsPPELGETEEGSIENTPSQID |
| Q8TEV9 | T666 | EPSD|PSP | SMCR8 | GFPAYELDPSHLLASRDISKtsLDNYSDTTSYVSSVASTSS |
| Q9BSB4 | S11 | PSP | ATG101 C12orf44 PP894 | __________MNCRSEVLEVsVEGRQVEEAMLAVLHTVLLH |
| Q9BSB4 | S203 | PSP | ATG101 C12orf44 PP894 | RDVQPYLYKISFQITDALGTsVTTTMRRLIKDTLAL_____ |
| Q9C0C7 | S465 | PSP | AMBRA1 DCAF3 KIAA1736 | VSLLSVLRQQEGGSQASVYTsATEGRGFPASGLATESDGGN |
| Q9C0C7 | S635 | PSP | AMBRA1 DCAF3 KIAA1736 | QLPPLERTEGQTPsSsRLELsssAsPQEERTVGVAFNQETG |
| Q9Y4P1 | S316 | EPSD|PSP | ATG4B APG4B AUTL1 KIAA0943 | DESFHCQHPPCRMSIAELDPsIAVGFFCKTEDDFNDWCQQV |
| Q9Y6D9 | S546 | PSP | MAD1L1 MAD1 TXBP181 | LERRALQGDYDQSRTKVLHMsLNPTSVARQRLREDHSQLQA |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 1.187939e-14 | 13.925 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 5.555778e-12 | 11.255 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 7.569434e-11 | 10.121 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.059841e-10 | 9.686 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 5.428303e-10 | 9.265 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 2.596492e-09 | 8.586 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 3.618309e-09 | 8.441 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 4.904204e-09 | 8.309 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 7.354602e-09 | 8.133 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.191056e-08 | 7.924 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.598483e-08 | 7.796 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 4.207545e-08 | 7.376 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 4.586349e-08 | 7.339 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 4.735979e-08 | 7.325 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 6.618703e-08 | 7.179 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.258206e-07 | 6.900 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 2.450962e-07 | 6.611 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 5.368305e-07 | 6.270 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 5.368305e-07 | 6.270 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.041201e-06 | 5.982 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 2.392975e-06 | 5.621 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.564271e-06 | 5.591 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 3.409769e-06 | 5.467 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 6.379673e-06 | 5.195 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 2.127545e-05 | 4.672 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 2.127545e-05 | 4.672 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 2.127545e-05 | 4.672 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 2.127545e-05 | 4.672 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.968897e-05 | 4.706 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.127420e-05 | 4.672 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 2.179005e-05 | 4.662 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 3.514430e-05 | 4.454 | 1 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 3.607418e-05 | 4.443 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 5.937004e-05 | 4.226 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 6.013795e-05 | 4.221 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 6.177802e-05 | 4.209 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 9.897523e-05 | 4.004 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 1.528166e-04 | 3.816 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.524855e-04 | 3.817 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 1.577816e-04 | 3.802 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 2.311715e-04 | 3.636 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 2.244792e-04 | 3.649 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 2.474992e-04 | 3.606 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 2.752007e-04 | 3.560 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.275406e-04 | 3.485 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.205241e-04 | 3.376 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 4.586305e-04 | 3.339 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 4.586305e-04 | 3.339 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 5.067197e-04 | 3.295 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 5.303795e-04 | 3.275 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 5.968023e-04 | 3.224 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 5.798058e-04 | 3.237 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 5.798058e-04 | 3.237 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 6.595489e-04 | 3.181 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 6.712092e-04 | 3.173 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 6.916497e-04 | 3.160 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 8.795644e-04 | 3.056 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 8.901875e-04 | 3.051 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 9.458672e-04 | 3.024 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 9.746489e-04 | 3.011 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 9.711354e-04 | 3.013 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 1.003068e-03 | 2.999 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.034173e-03 | 2.985 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.178138e-03 | 2.929 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 1.322577e-03 | 2.879 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 1.412203e-03 | 2.850 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.452764e-03 | 2.838 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 1.456964e-03 | 2.837 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 1.456964e-03 | 2.837 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 1.412203e-03 | 2.850 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.658917e-03 | 2.780 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 1.737464e-03 | 2.760 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.714313e-03 | 2.766 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.741027e-03 | 2.759 | 1 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 2.169631e-03 | 2.664 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.148229e-03 | 2.668 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.338613e-03 | 2.631 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 2.379376e-03 | 2.624 | 1 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.430647e-03 | 2.614 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 2.623194e-03 | 2.581 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 2.623194e-03 | 2.581 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 2.722382e-03 | 2.565 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.753849e-03 | 2.560 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.969241e-03 | 2.527 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 2.937317e-03 | 2.532 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 3.050597e-03 | 2.516 | 1 | 1 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 3.433670e-03 | 2.464 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 3.433670e-03 | 2.464 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 3.438375e-03 | 2.464 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 3.786122e-03 | 2.422 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.975940e-03 | 2.401 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 4.175753e-03 | 2.379 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 4.686274e-03 | 2.329 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 4.830025e-03 | 2.316 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 4.866848e-03 | 2.313 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 5.181507e-03 | 2.286 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 5.654769e-03 | 2.248 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 5.654769e-03 | 2.248 | 1 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 5.588074e-03 | 2.253 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 5.947571e-03 | 2.226 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 5.947571e-03 | 2.226 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 5.947571e-03 | 2.226 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 5.962099e-03 | 2.225 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 6.388109e-03 | 2.195 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 6.388109e-03 | 2.195 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 6.151284e-03 | 2.211 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 6.151284e-03 | 2.211 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 6.526454e-03 | 2.185 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 6.671304e-03 | 2.176 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.679717e-03 | 2.175 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 7.232514e-03 | 2.141 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 7.232514e-03 | 2.141 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 7.232514e-03 | 2.141 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 6.903909e-03 | 2.161 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 6.895633e-03 | 2.161 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 7.208088e-03 | 2.142 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 7.208088e-03 | 2.142 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 7.273996e-03 | 2.138 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 7.338098e-03 | 2.134 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 7.805424e-03 | 2.108 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 7.805424e-03 | 2.108 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 7.898051e-03 | 2.102 | 1 | 1 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 8.518419e-03 | 2.070 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 8.518419e-03 | 2.070 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 8.579155e-03 | 2.067 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 8.465809e-03 | 2.072 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 8.587852e-03 | 2.066 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 8.587852e-03 | 2.066 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 8.643481e-03 | 2.063 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 8.967206e-03 | 2.047 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 9.035045e-03 | 2.044 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 9.274341e-03 | 2.033 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 1.018632e-02 | 1.992 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 1.018632e-02 | 1.992 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 9.722461e-03 | 2.012 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 1.018632e-02 | 1.992 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 9.591404e-03 | 2.018 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 9.607180e-03 | 2.017 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 9.815064e-03 | 2.008 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 1.039862e-02 | 1.983 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.039862e-02 | 1.983 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 1.093977e-02 | 1.961 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.093977e-02 | 1.961 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 1.109001e-02 | 1.955 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.130917e-02 | 1.947 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.156367e-02 | 1.937 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 1.233456e-02 | 1.909 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 1.365801e-02 | 1.865 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 1.365801e-02 | 1.865 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 1.365801e-02 | 1.865 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 1.365801e-02 | 1.865 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.345701e-02 | 1.871 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.345701e-02 | 1.871 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.357899e-02 | 1.867 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 1.365801e-02 | 1.865 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.265938e-02 | 1.898 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 1.379928e-02 | 1.860 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.379928e-02 | 1.860 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.383584e-02 | 1.859 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 1.410161e-02 | 1.851 | 1 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 1.549835e-02 | 1.810 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.563201e-02 | 1.806 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.640372e-02 | 1.785 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.640372e-02 | 1.785 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.588236e-02 | 1.799 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.539965e-02 | 1.812 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.540099e-02 | 1.812 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.549835e-02 | 1.810 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 1.553444e-02 | 1.809 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.714129e-02 | 1.766 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.730706e-02 | 1.762 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.730706e-02 | 1.762 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 1.753861e-02 | 1.756 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.753861e-02 | 1.756 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 1.809139e-02 | 1.743 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.809139e-02 | 1.743 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 1.809139e-02 | 1.743 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 1.809139e-02 | 1.743 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.809139e-02 | 1.743 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.871268e-02 | 1.728 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 1.876151e-02 | 1.727 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 1.876151e-02 | 1.727 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 2.175533e-02 | 1.662 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 2.175533e-02 | 1.662 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.132880e-02 | 1.671 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.156074e-02 | 1.666 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 2.051974e-02 | 1.688 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.937321e-02 | 1.713 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 1.979837e-02 | 1.703 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 2.015798e-02 | 1.696 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.274481e-02 | 1.643 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.579552e-02 | 1.588 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.579552e-02 | 1.588 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.579552e-02 | 1.588 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 2.579552e-02 | 1.588 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 2.579552e-02 | 1.588 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.579552e-02 | 1.588 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.579552e-02 | 1.588 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.372201e-02 | 1.625 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 2.440549e-02 | 1.613 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 2.412198e-02 | 1.618 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.442659e-02 | 1.612 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.514045e-02 | 1.600 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 2.571557e-02 | 1.590 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 2.477400e-02 | 1.606 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.481926e-02 | 1.605 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 2.372201e-02 | 1.625 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 2.372201e-02 | 1.625 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 2.372201e-02 | 1.625 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.568700e-02 | 1.590 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.375894e-02 | 1.624 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.375755e-02 | 1.624 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.435178e-02 | 1.613 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.342287e-02 | 1.630 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 2.489690e-02 | 1.604 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.571557e-02 | 1.590 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 2.655634e-02 | 1.576 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.657649e-02 | 1.576 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 2.705689e-02 | 1.568 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.717314e-02 | 1.566 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.736931e-02 | 1.563 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 2.739576e-02 | 1.562 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 2.741024e-02 | 1.562 | 0 | 0 |
| S Phase | R-HSA-69242 | 2.741024e-02 | 1.562 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.813850e-02 | 1.551 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 3.214139e-02 | 1.493 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 3.214139e-02 | 1.493 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 3.202300e-02 | 1.495 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 3.062251e-02 | 1.514 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 3.353160e-02 | 1.475 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 3.353160e-02 | 1.475 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 2.912785e-02 | 1.536 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 3.316838e-02 | 1.479 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 2.875553e-02 | 1.541 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 3.214139e-02 | 1.493 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 3.127614e-02 | 1.505 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 3.302327e-02 | 1.481 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 3.302327e-02 | 1.481 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 3.302327e-02 | 1.481 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 3.142337e-02 | 1.503 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 3.214139e-02 | 1.493 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 3.214139e-02 | 1.493 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.875553e-02 | 1.541 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 3.016317e-02 | 1.521 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.192209e-02 | 1.496 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 3.354380e-02 | 1.474 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 3.354380e-02 | 1.474 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 3.462981e-02 | 1.461 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 3.492146e-02 | 1.457 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 3.557464e-02 | 1.449 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 3.611902e-02 | 1.442 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 3.611902e-02 | 1.442 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 3.656777e-02 | 1.437 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 3.758975e-02 | 1.425 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.758975e-02 | 1.425 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 3.758975e-02 | 1.425 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.892980e-02 | 1.410 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 3.905828e-02 | 1.408 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 3.905828e-02 | 1.408 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 3.905828e-02 | 1.408 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 3.905828e-02 | 1.408 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 3.905828e-02 | 1.408 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 3.932232e-02 | 1.405 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 3.991037e-02 | 1.399 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 3.991037e-02 | 1.399 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 3.991037e-02 | 1.399 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.043356e-02 | 1.393 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 4.094321e-02 | 1.388 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 4.094321e-02 | 1.388 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 4.107117e-02 | 1.386 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 4.875047e-02 | 1.312 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 5.001324e-02 | 1.301 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 5.001324e-02 | 1.301 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 5.001324e-02 | 1.301 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 5.001324e-02 | 1.301 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 5.001324e-02 | 1.301 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 4.799747e-02 | 1.319 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 4.886605e-02 | 1.311 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 4.863902e-02 | 1.313 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 4.937677e-02 | 1.306 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 4.875047e-02 | 1.312 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.001324e-02 | 1.301 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 4.985737e-02 | 1.302 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 4.932882e-02 | 1.307 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 4.373664e-02 | 1.359 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 4.504857e-02 | 1.346 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.001324e-02 | 1.301 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 4.373664e-02 | 1.359 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 4.504857e-02 | 1.346 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 4.975044e-02 | 1.303 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 4.631943e-02 | 1.334 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 4.875047e-02 | 1.312 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 4.373664e-02 | 1.359 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 5.001324e-02 | 1.301 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 5.227138e-02 | 1.282 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 5.259200e-02 | 1.279 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 5.259200e-02 | 1.279 | 0 | 0 |
| Defective Base Excision Repair Associated with OGG1 | R-HSA-9656249 | 5.358202e-02 | 1.271 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 5.358202e-02 | 1.271 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 5.358202e-02 | 1.271 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 5.424206e-02 | 1.266 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.496198e-02 | 1.260 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 5.496198e-02 | 1.260 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 5.505681e-02 | 1.259 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 5.505681e-02 | 1.259 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 5.585028e-02 | 1.253 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 5.588535e-02 | 1.253 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 5.588535e-02 | 1.253 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 5.609083e-02 | 1.251 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 5.677805e-02 | 1.246 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.677805e-02 | 1.246 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 5.677805e-02 | 1.246 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.677805e-02 | 1.246 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 5.743207e-02 | 1.241 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 5.745646e-02 | 1.241 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 5.745646e-02 | 1.241 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 5.745646e-02 | 1.241 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 5.745646e-02 | 1.241 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 5.806018e-02 | 1.236 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 5.806018e-02 | 1.236 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 6.290122e-02 | 1.201 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 6.290122e-02 | 1.201 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.171523e-02 | 1.144 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 5.988147e-02 | 1.223 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 7.272868e-02 | 1.138 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 6.600351e-02 | 1.180 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 6.600351e-02 | 1.180 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 7.023432e-02 | 1.153 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.966070e-02 | 1.157 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 6.148397e-02 | 1.211 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 6.148397e-02 | 1.211 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 6.790496e-02 | 1.168 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 7.039944e-02 | 1.152 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 6.819946e-02 | 1.166 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 7.171523e-02 | 1.144 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 7.125327e-02 | 1.147 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 7.431763e-02 | 1.129 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 6.052927e-02 | 1.218 | 1 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 7.143372e-02 | 1.146 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 7.171523e-02 | 1.144 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 6.132157e-02 | 1.212 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 6.795487e-02 | 1.168 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 6.425512e-02 | 1.192 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 6.795487e-02 | 1.168 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 7.431763e-02 | 1.129 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 6.442601e-02 | 1.191 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 6.191720e-02 | 1.208 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 6.390249e-02 | 1.194 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 6.795487e-02 | 1.168 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 6.425512e-02 | 1.192 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 7.532881e-02 | 1.123 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 7.545997e-02 | 1.122 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 7.569529e-02 | 1.121 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 7.763607e-02 | 1.110 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 7.763607e-02 | 1.110 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 7.896851e-02 | 1.103 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 7.937232e-02 | 1.100 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 7.976893e-02 | 1.098 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.976893e-02 | 1.098 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 7.976893e-02 | 1.098 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.983009e-02 | 1.098 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.983009e-02 | 1.098 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 8.113725e-02 | 1.091 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 8.128648e-02 | 1.090 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 8.128648e-02 | 1.090 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 8.305593e-02 | 1.081 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 8.329482e-02 | 1.079 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 8.329482e-02 | 1.079 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 8.329482e-02 | 1.079 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 8.329482e-02 | 1.079 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 8.329482e-02 | 1.079 | 0 | 0 |
| Defective OGG1 Substrate Binding | R-HSA-9656255 | 1.159226e-01 | 0.936 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.159226e-01 | 0.936 | 0 | 0 |
| Defective OGG1 Localization | R-HSA-9657050 | 1.159226e-01 | 0.936 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 8.801770e-02 | 1.055 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 8.801770e-02 | 1.055 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 8.801770e-02 | 1.055 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 8.801770e-02 | 1.055 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 8.801770e-02 | 1.055 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 8.801770e-02 | 1.055 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 8.801770e-02 | 1.055 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 8.801770e-02 | 1.055 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 8.801770e-02 | 1.055 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 8.801770e-02 | 1.055 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.013243e-01 | 0.994 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 1.013243e-01 | 0.994 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 1.013243e-01 | 0.994 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 9.686429e-02 | 1.014 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 9.686429e-02 | 1.014 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 9.686429e-02 | 1.014 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 1.164706e-01 | 0.934 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.848969e-02 | 1.053 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 8.848969e-02 | 1.053 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 1.039577e-01 | 0.983 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 1.039577e-01 | 0.983 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.125712e-02 | 1.040 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 9.117968e-02 | 1.040 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.056277e-01 | 0.976 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.056277e-01 | 0.976 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 1.045742e-01 | 0.981 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 1.091441e-01 | 0.962 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.056277e-01 | 0.976 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.135644e-01 | 0.945 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.135644e-01 | 0.945 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 1.013243e-01 | 0.994 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 1.164706e-01 | 0.934 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.163416e-01 | 0.934 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 9.432896e-02 | 1.025 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 9.877885e-02 | 1.005 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.144118e-01 | 0.942 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 1.013243e-01 | 0.994 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 9.251987e-02 | 1.034 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 1.020695e-01 | 0.991 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 1.084433e-01 | 0.965 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 9.205731e-02 | 1.036 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 1.135644e-01 | 0.945 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 9.507558e-02 | 1.022 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.018926e-01 | 0.992 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.813633e-02 | 1.008 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 1.039577e-01 | 0.983 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 1.045742e-01 | 0.981 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 9.629931e-02 | 1.016 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 1.135644e-01 | 0.945 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 8.801770e-02 | 1.055 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 9.686429e-02 | 1.014 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.164706e-01 | 0.934 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 1.164706e-01 | 0.934 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 8.848969e-02 | 1.053 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 1.023622e-01 | 0.990 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 8.900582e-02 | 1.051 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 1.123227e-01 | 0.950 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 9.816396e-02 | 1.008 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 9.341312e-02 | 1.030 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 1.013243e-01 | 0.994 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 8.908367e-02 | 1.050 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 8.848969e-02 | 1.053 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 8.848969e-02 | 1.053 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 9.686429e-02 | 1.014 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.164706e-01 | 0.934 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 1.174315e-01 | 0.930 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 1.174315e-01 | 0.930 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.174315e-01 | 0.930 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 1.174315e-01 | 0.930 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.176098e-01 | 0.930 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 1.200930e-01 | 0.920 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 1.206633e-01 | 0.918 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.206633e-01 | 0.918 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.206633e-01 | 0.918 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.206633e-01 | 0.918 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 1.247570e-01 | 0.904 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 1.247570e-01 | 0.904 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 1.264186e-01 | 0.898 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.271891e-01 | 0.896 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.271891e-01 | 0.896 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.274877e-01 | 0.895 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.274877e-01 | 0.895 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 1.274877e-01 | 0.895 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 1.274877e-01 | 0.895 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 1.274877e-01 | 0.895 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 1.274877e-01 | 0.895 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 1.282916e-01 | 0.892 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 1.293747e-01 | 0.888 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 1.307418e-01 | 0.884 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 1.307418e-01 | 0.884 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 1.310673e-01 | 0.883 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.310673e-01 | 0.883 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 1.316137e-01 | 0.881 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 1.316137e-01 | 0.881 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 1.316137e-01 | 0.881 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 1.316137e-01 | 0.881 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 1.316137e-01 | 0.881 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 1.316137e-01 | 0.881 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.324264e-01 | 0.878 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.335119e-01 | 0.874 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 1.342742e-01 | 0.872 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.343521e-01 | 0.872 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 1.353397e-01 | 0.869 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.356481e-01 | 0.868 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 1.356481e-01 | 0.868 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 1.356481e-01 | 0.868 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.356481e-01 | 0.868 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.356481e-01 | 0.868 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 1.357851e-01 | 0.867 | 1 | 1 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 1.376460e-01 | 0.861 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 1.376460e-01 | 0.861 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 1.376460e-01 | 0.861 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 1.376460e-01 | 0.861 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 1.376460e-01 | 0.861 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 1.376460e-01 | 0.861 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 1.376460e-01 | 0.861 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 1.376460e-01 | 0.861 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.385344e-01 | 0.858 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 1.385388e-01 | 0.858 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.419161e-01 | 0.848 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.419161e-01 | 0.848 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.428449e-01 | 0.845 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 1.428449e-01 | 0.845 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 1.695367e-01 | 0.771 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 1.695367e-01 | 0.771 | 0 | 0 |
| IRS activation | R-HSA-74713 | 2.137987e-01 | 0.670 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 2.137987e-01 | 0.670 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 2.137987e-01 | 0.670 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 2.137987e-01 | 0.670 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.557483e-01 | 0.808 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 1.557483e-01 | 0.808 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 1.557483e-01 | 0.808 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 1.557483e-01 | 0.808 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 1.557483e-01 | 0.808 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.857230e-01 | 0.731 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.857230e-01 | 0.731 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 1.857230e-01 | 0.731 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 1.857230e-01 | 0.731 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 1.602317e-01 | 0.795 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 1.602317e-01 | 0.795 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 2.170365e-01 | 0.663 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 2.089450e-01 | 0.680 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 2.089450e-01 | 0.680 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 2.089450e-01 | 0.680 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 1.454517e-01 | 0.837 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 1.691964e-01 | 0.772 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 1.763202e-01 | 0.754 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 2.058049e-01 | 0.687 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.927200e-01 | 0.715 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.517636e-01 | 0.819 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.570399e-01 | 0.804 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 1.605493e-01 | 0.794 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 2.114055e-01 | 0.675 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.605493e-01 | 0.794 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.724824e-01 | 0.763 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.574873e-01 | 0.803 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 2.097013e-01 | 0.678 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 1.853608e-01 | 0.732 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 2.089450e-01 | 0.680 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 2.089450e-01 | 0.680 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 1.691964e-01 | 0.772 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.745897e-01 | 0.758 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.974711e-01 | 0.704 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.037798e-01 | 0.691 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 1.691964e-01 | 0.772 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 1.520083e-01 | 0.818 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 2.037798e-01 | 0.691 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 2.110790e-01 | 0.676 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.006565e-01 | 0.698 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 1.520083e-01 | 0.818 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 2.088301e-01 | 0.680 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 1.557483e-01 | 0.808 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.857230e-01 | 0.731 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 2.170365e-01 | 0.663 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 1.840572e-01 | 0.735 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 1.605493e-01 | 0.794 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 1.763202e-01 | 0.754 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.509884e-01 | 0.821 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.965826e-01 | 0.706 | 1 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.605493e-01 | 0.794 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.845524e-01 | 0.734 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 1.772427e-01 | 0.751 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 1.454517e-01 | 0.837 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 2.089450e-01 | 0.680 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 1.691964e-01 | 0.772 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.729973e-01 | 0.762 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.142008e-01 | 0.669 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 1.540359e-01 | 0.812 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.669262e-01 | 0.777 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.454517e-01 | 0.837 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 2.137987e-01 | 0.670 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 1.574873e-01 | 0.803 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.509884e-01 | 0.821 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 2.131673e-01 | 0.671 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.602317e-01 | 0.795 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.563079e-01 | 0.806 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 2.097013e-01 | 0.678 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.833674e-01 | 0.737 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.170365e-01 | 0.663 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 2.089450e-01 | 0.680 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 1.616909e-01 | 0.791 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.991320e-01 | 0.701 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 2.149078e-01 | 0.668 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 1.574873e-01 | 0.803 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.495414e-01 | 0.825 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 2.137987e-01 | 0.670 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 1.857230e-01 | 0.731 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.137987e-01 | 0.670 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 1.454517e-01 | 0.837 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.708086e-01 | 0.767 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 1.574873e-01 | 0.803 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 2.098077e-01 | 0.678 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 1.574873e-01 | 0.803 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 1.840572e-01 | 0.735 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.178325e-01 | 0.662 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 2.178325e-01 | 0.662 | 0 | 0 |
| Activation, translocation and oligomerization of BAX | R-HSA-114294 | 2.184132e-01 | 0.661 | 0 | 0 |
| Defective OGG1 Substrate Processing | R-HSA-9656256 | 2.184132e-01 | 0.661 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 2.184132e-01 | 0.661 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 2.184132e-01 | 0.661 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.184132e-01 | 0.661 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.184132e-01 | 0.661 | 0 | 0 |
| SARS-CoV-1 targets PDZ proteins in cell-cell junction | R-HSA-9692912 | 2.184132e-01 | 0.661 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.184132e-01 | 0.661 | 0 | 0 |
| TGFBR2 MSI Frameshift Mutants in Cancer | R-HSA-3642279 | 2.184132e-01 | 0.661 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.184132e-01 | 0.661 | 0 | 0 |
| Blockage of phagosome acidification | R-HSA-9636467 | 2.184132e-01 | 0.661 | 0 | 0 |
| Defective MOGS causes CDG-2b | R-HSA-4793954 | 2.184132e-01 | 0.661 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 2.184132e-01 | 0.661 | 0 | 0 |
| Defective F8 binding to von Willebrand factor | R-HSA-9672393 | 2.184132e-01 | 0.661 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 2.184132e-01 | 0.661 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.184132e-01 | 0.661 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 2.198746e-01 | 0.658 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 2.202049e-01 | 0.657 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 2.224450e-01 | 0.653 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 2.229554e-01 | 0.652 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 2.230092e-01 | 0.652 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 2.240606e-01 | 0.650 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 2.248523e-01 | 0.648 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.250883e-01 | 0.648 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.250883e-01 | 0.648 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 2.250883e-01 | 0.648 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.260249e-01 | 0.646 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 2.263090e-01 | 0.645 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 2.266596e-01 | 0.645 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 2.266596e-01 | 0.645 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 2.272134e-01 | 0.644 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.298959e-01 | 0.638 | 0 | 0 |
| Nef mediated downregulation of CD28 cell surface expression | R-HSA-164939 | 3.090273e-01 | 0.510 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 3.090273e-01 | 0.510 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 3.090273e-01 | 0.510 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 3.090273e-01 | 0.510 | 0 | 0 |
| Defective APRT disrupts adenine salvage | R-HSA-9734195 | 3.090273e-01 | 0.510 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 3.090273e-01 | 0.510 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 3.090273e-01 | 0.510 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 3.090273e-01 | 0.510 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 3.090273e-01 | 0.510 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 3.090273e-01 | 0.510 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 3.090273e-01 | 0.510 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 3.090273e-01 | 0.510 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 2.589627e-01 | 0.587 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.589627e-01 | 0.587 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 2.589627e-01 | 0.587 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 2.589627e-01 | 0.587 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 2.589627e-01 | 0.587 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.891407e-01 | 0.410 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 3.891407e-01 | 0.410 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 3.891407e-01 | 0.410 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 3.891407e-01 | 0.410 | 0 | 0 |
| Defective F8 cleavage by thrombin | R-HSA-9672391 | 3.891407e-01 | 0.410 | 0 | 0 |
| Defective SLC12A1 causes Bartter syndrome 1 (BS1) | R-HSA-5619104 | 3.891407e-01 | 0.410 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 3.891407e-01 | 0.410 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 3.891407e-01 | 0.410 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 3.891407e-01 | 0.410 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.042253e-01 | 0.517 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 3.042253e-01 | 0.517 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 3.042253e-01 | 0.517 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.347152e-01 | 0.629 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.347152e-01 | 0.629 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 2.822725e-01 | 0.549 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 3.489570e-01 | 0.457 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 3.489570e-01 | 0.457 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 3.489570e-01 | 0.457 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 4.599697e-01 | 0.337 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.599697e-01 | 0.337 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.599697e-01 | 0.337 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 4.599697e-01 | 0.337 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.599697e-01 | 0.337 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 4.599697e-01 | 0.337 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 4.599697e-01 | 0.337 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 4.599697e-01 | 0.337 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.599697e-01 | 0.337 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 2.881916e-01 | 0.540 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 3.926728e-01 | 0.406 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 3.926728e-01 | 0.406 | 0 | 0 |
| RSK activation | R-HSA-444257 | 3.926728e-01 | 0.406 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 3.926728e-01 | 0.406 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 3.926728e-01 | 0.406 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 3.926728e-01 | 0.406 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.449281e-01 | 0.611 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.449281e-01 | 0.611 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.449281e-01 | 0.611 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.449281e-01 | 0.611 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 3.489013e-01 | 0.457 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 3.155551e-01 | 0.501 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 2.883328e-01 | 0.540 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 2.883328e-01 | 0.540 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.883328e-01 | 0.540 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 2.652493e-01 | 0.576 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 2.652493e-01 | 0.576 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 3.431201e-01 | 0.465 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 3.820673e-01 | 0.418 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 4.350072e-01 | 0.362 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 4.350072e-01 | 0.362 | 0 | 0 |
| Hypusine synthesis from eIF5A-lysine | R-HSA-204626 | 4.350072e-01 | 0.362 | 0 | 0 |
| 5-Phosphoribose 1-diphosphate biosynthesis | R-HSA-73843 | 4.350072e-01 | 0.362 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.823984e-01 | 0.549 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 3.982688e-01 | 0.400 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 3.840341e-01 | 0.416 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.231600e-01 | 0.491 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 3.231600e-01 | 0.491 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 4.470296e-01 | 0.350 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 2.522667e-01 | 0.598 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 3.496727e-01 | 0.456 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 4.255878e-01 | 0.371 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.400522e-01 | 0.468 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.930832e-01 | 0.406 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 3.996709e-01 | 0.398 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 3.149406e-01 | 0.502 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 4.362296e-01 | 0.360 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 3.835565e-01 | 0.416 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 4.556945e-01 | 0.341 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 3.624910e-01 | 0.441 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 3.624910e-01 | 0.441 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 4.258605e-01 | 0.371 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 4.258605e-01 | 0.371 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.453052e-01 | 0.351 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 4.335649e-01 | 0.363 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 2.730508e-01 | 0.564 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 3.835565e-01 | 0.416 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 3.835565e-01 | 0.416 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 3.135195e-01 | 0.504 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 3.135195e-01 | 0.504 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 2.364228e-01 | 0.626 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 2.736580e-01 | 0.563 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 4.319922e-01 | 0.365 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 3.064398e-01 | 0.514 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 2.822725e-01 | 0.549 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 3.155546e-01 | 0.501 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 2.841747e-01 | 0.546 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 3.418608e-01 | 0.466 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 4.234474e-01 | 0.373 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 3.498377e-01 | 0.456 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 3.798543e-01 | 0.420 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 3.418608e-01 | 0.466 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 2.867113e-01 | 0.543 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 2.859763e-01 | 0.544 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 2.419899e-01 | 0.616 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.155551e-01 | 0.501 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.315150e-01 | 0.479 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 2.449281e-01 | 0.611 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 3.489570e-01 | 0.457 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 2.881916e-01 | 0.540 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 3.820673e-01 | 0.418 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 4.350072e-01 | 0.362 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 4.525804e-01 | 0.344 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 2.689709e-01 | 0.570 | 1 | 0 |
| Signal amplification | R-HSA-392518 | 3.930832e-01 | 0.406 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 4.471473e-01 | 0.350 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 3.724721e-01 | 0.429 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 3.155546e-01 | 0.501 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 3.820673e-01 | 0.418 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 4.199756e-01 | 0.377 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 3.926728e-01 | 0.406 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.503462e-01 | 0.601 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.403849e-01 | 0.468 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 2.785208e-01 | 0.555 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 4.362296e-01 | 0.360 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.822725e-01 | 0.549 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 3.926728e-01 | 0.406 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 4.362296e-01 | 0.360 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 3.681920e-01 | 0.434 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.385240e-01 | 0.470 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 2.347152e-01 | 0.629 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.155551e-01 | 0.501 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.599431e-01 | 0.444 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 3.742101e-01 | 0.427 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 2.689709e-01 | 0.570 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.785208e-01 | 0.555 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 2.668974e-01 | 0.574 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 2.419899e-01 | 0.616 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.358973e-01 | 0.474 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 2.501880e-01 | 0.602 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 2.822725e-01 | 0.549 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 3.489570e-01 | 0.457 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 4.097970e-01 | 0.387 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 3.930832e-01 | 0.406 | 1 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 3.742101e-01 | 0.427 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 4.576112e-01 | 0.340 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 2.881916e-01 | 0.540 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.930410e-01 | 0.533 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 4.147006e-01 | 0.382 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 4.319922e-01 | 0.365 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 4.194737e-01 | 0.377 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 3.220367e-01 | 0.492 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 2.875700e-01 | 0.541 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 2.347152e-01 | 0.629 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 2.881916e-01 | 0.540 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 4.255878e-01 | 0.371 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 3.951431e-01 | 0.403 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.807284e-01 | 0.552 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 3.155551e-01 | 0.501 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 4.556945e-01 | 0.341 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 3.470522e-01 | 0.460 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 3.863013e-01 | 0.413 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 3.621542e-01 | 0.441 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 4.073084e-01 | 0.390 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 2.576673e-01 | 0.589 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 2.332312e-01 | 0.632 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 3.867275e-01 | 0.413 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 2.881916e-01 | 0.540 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 4.350072e-01 | 0.362 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 3.835565e-01 | 0.416 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 4.142360e-01 | 0.383 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 3.599431e-01 | 0.444 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 2.785208e-01 | 0.555 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 2.957299e-01 | 0.529 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.957299e-01 | 0.529 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 3.090273e-01 | 0.510 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 3.891407e-01 | 0.410 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 3.891407e-01 | 0.410 | 0 | 0 |
| Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization | R-HSA-180897 | 3.891407e-01 | 0.410 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.489570e-01 | 0.457 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 3.489570e-01 | 0.457 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 4.599697e-01 | 0.337 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 4.599697e-01 | 0.337 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 3.489013e-01 | 0.457 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 4.350072e-01 | 0.362 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 3.070331e-01 | 0.513 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 2.501880e-01 | 0.602 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.135195e-01 | 0.504 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 4.470296e-01 | 0.350 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 4.080790e-01 | 0.389 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 3.798543e-01 | 0.420 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 4.194737e-01 | 0.377 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 4.392144e-01 | 0.357 | 1 | 1 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 4.097815e-01 | 0.387 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 3.408659e-01 | 0.467 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 3.408659e-01 | 0.467 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.315150e-01 | 0.479 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 2.623457e-01 | 0.581 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 3.798543e-01 | 0.420 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 2.421647e-01 | 0.616 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 2.650206e-01 | 0.577 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 3.358973e-01 | 0.474 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 4.080790e-01 | 0.389 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 2.823054e-01 | 0.549 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 4.362296e-01 | 0.360 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.498377e-01 | 0.456 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 4.258605e-01 | 0.371 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 2.532037e-01 | 0.597 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 4.046879e-01 | 0.393 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 3.042253e-01 | 0.517 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 3.489570e-01 | 0.457 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 3.820673e-01 | 0.418 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 4.350072e-01 | 0.362 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 4.350072e-01 | 0.362 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.046879e-01 | 0.393 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 2.765985e-01 | 0.558 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 2.859763e-01 | 0.544 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.588466e-01 | 0.338 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.319922e-01 | 0.365 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.556945e-01 | 0.341 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 2.589627e-01 | 0.587 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 2.822725e-01 | 0.549 | 0 | 0 |
| Intracellular oxygen transport | R-HSA-8981607 | 4.599697e-01 | 0.337 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 2.881916e-01 | 0.540 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 3.926728e-01 | 0.406 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 3.926728e-01 | 0.406 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 4.470296e-01 | 0.350 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 4.470296e-01 | 0.350 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 3.982688e-01 | 0.400 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 3.982688e-01 | 0.400 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.599697e-01 | 0.337 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.650206e-01 | 0.577 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 3.820673e-01 | 0.418 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 4.148383e-01 | 0.382 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 3.624910e-01 | 0.441 | 0 | 0 |
| Diseases of Base Excision Repair | R-HSA-9605308 | 2.589627e-01 | 0.587 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 3.914059e-01 | 0.407 | 0 | 0 |
| NTRK3 as a dependence receptor | R-HSA-9603505 | 3.090273e-01 | 0.510 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.891407e-01 | 0.410 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 2.347152e-01 | 0.629 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 3.489570e-01 | 0.457 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 4.599697e-01 | 0.337 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 3.982688e-01 | 0.400 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 4.255878e-01 | 0.371 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 4.525804e-01 | 0.344 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 2.452036e-01 | 0.610 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 3.242834e-01 | 0.489 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 4.599697e-01 | 0.337 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 3.926728e-01 | 0.406 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 4.350072e-01 | 0.362 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 4.148383e-01 | 0.382 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.086337e-01 | 0.389 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 3.930832e-01 | 0.406 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.484966e-01 | 0.605 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.155551e-01 | 0.501 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 4.470296e-01 | 0.350 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 2.452036e-01 | 0.610 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.596566e-01 | 0.338 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 2.873115e-01 | 0.542 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 2.493310e-01 | 0.603 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 3.658732e-01 | 0.437 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 3.155546e-01 | 0.501 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 2.421647e-01 | 0.616 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 2.650206e-01 | 0.577 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 4.605117e-01 | 0.337 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 4.606969e-01 | 0.337 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 4.607755e-01 | 0.337 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 4.607755e-01 | 0.337 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.697350e-01 | 0.328 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 4.707423e-01 | 0.327 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 4.748685e-01 | 0.323 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 4.756930e-01 | 0.323 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.756930e-01 | 0.323 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 4.756930e-01 | 0.323 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 4.756930e-01 | 0.323 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 4.756930e-01 | 0.323 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.756930e-01 | 0.323 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 4.756930e-01 | 0.323 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 4.756930e-01 | 0.323 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 4.756930e-01 | 0.323 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.756930e-01 | 0.323 | 1 | 1 |
| Signaling by Leptin | R-HSA-2586552 | 4.756930e-01 | 0.323 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 4.760255e-01 | 0.322 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 4.772179e-01 | 0.321 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 4.777912e-01 | 0.321 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 4.777912e-01 | 0.321 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 4.783268e-01 | 0.320 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 4.784851e-01 | 0.320 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 4.784851e-01 | 0.320 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 4.784851e-01 | 0.320 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 4.784851e-01 | 0.320 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 4.791444e-01 | 0.320 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 4.888141e-01 | 0.311 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 4.926388e-01 | 0.307 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 4.941301e-01 | 0.306 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 4.968400e-01 | 0.304 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 4.993552e-01 | 0.302 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 4.997153e-01 | 0.301 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 5.017662e-01 | 0.299 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 5.021816e-01 | 0.299 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 5.051901e-01 | 0.297 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 5.051901e-01 | 0.297 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 5.090752e-01 | 0.293 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 5.090752e-01 | 0.293 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 5.108925e-01 | 0.292 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 5.124610e-01 | 0.290 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 5.135728e-01 | 0.289 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 5.145434e-01 | 0.289 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 5.145434e-01 | 0.289 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 5.145434e-01 | 0.289 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 5.145434e-01 | 0.289 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 5.145434e-01 | 0.289 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 5.145434e-01 | 0.289 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 5.145434e-01 | 0.289 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 5.145434e-01 | 0.289 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 5.145434e-01 | 0.289 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 5.145434e-01 | 0.289 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 5.152552e-01 | 0.288 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 5.165474e-01 | 0.287 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 5.181064e-01 | 0.286 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 5.188677e-01 | 0.285 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 5.203396e-01 | 0.284 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 5.203396e-01 | 0.284 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 5.203396e-01 | 0.284 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 5.214239e-01 | 0.283 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 5.225897e-01 | 0.282 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 5.225897e-01 | 0.282 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 5.225897e-01 | 0.282 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 5.225897e-01 | 0.282 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 5.225897e-01 | 0.282 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 5.225897e-01 | 0.282 | 0 | 0 |
| Signaling by LRP5 mutants | R-HSA-5339717 | 5.225897e-01 | 0.282 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 5.225897e-01 | 0.282 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 5.225897e-01 | 0.282 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 5.225897e-01 | 0.282 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 5.225897e-01 | 0.282 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 5.225897e-01 | 0.282 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 5.225897e-01 | 0.282 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 5.225897e-01 | 0.282 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 5.225897e-01 | 0.282 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 5.225897e-01 | 0.282 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 5.248408e-01 | 0.280 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 5.248408e-01 | 0.280 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 5.263364e-01 | 0.279 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 5.294236e-01 | 0.276 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 5.306394e-01 | 0.275 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 5.306394e-01 | 0.275 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 5.306394e-01 | 0.275 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 5.311580e-01 | 0.275 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 5.311580e-01 | 0.275 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 5.334769e-01 | 0.273 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 5.386949e-01 | 0.269 | 0 | 0 |
| PKA activation | R-HSA-163615 | 5.386949e-01 | 0.269 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 5.386949e-01 | 0.269 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 5.386949e-01 | 0.269 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 5.386949e-01 | 0.269 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 5.398184e-01 | 0.268 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 5.398447e-01 | 0.268 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 5.406204e-01 | 0.267 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 5.470377e-01 | 0.262 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 5.470377e-01 | 0.262 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 5.475500e-01 | 0.262 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 5.507323e-01 | 0.259 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 5.509984e-01 | 0.259 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 5.514370e-01 | 0.259 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 5.514370e-01 | 0.259 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.514370e-01 | 0.259 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.514370e-01 | 0.259 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 5.514370e-01 | 0.259 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 5.514370e-01 | 0.259 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 5.552324e-01 | 0.256 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 5.554258e-01 | 0.255 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 5.554258e-01 | 0.255 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 5.652897e-01 | 0.248 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 5.672615e-01 | 0.246 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 5.672615e-01 | 0.246 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 5.672615e-01 | 0.246 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 5.672615e-01 | 0.246 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 5.672615e-01 | 0.246 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 5.672615e-01 | 0.246 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 5.672615e-01 | 0.246 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 5.672615e-01 | 0.246 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 5.687257e-01 | 0.245 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.687257e-01 | 0.245 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 5.720172e-01 | 0.243 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.779517e-01 | 0.238 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 5.779517e-01 | 0.238 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.779517e-01 | 0.238 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 5.779517e-01 | 0.238 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.779517e-01 | 0.238 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.779517e-01 | 0.238 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 5.779517e-01 | 0.238 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.779517e-01 | 0.238 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 5.779517e-01 | 0.238 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.779517e-01 | 0.238 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 5.779517e-01 | 0.238 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 5.779517e-01 | 0.238 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 5.779517e-01 | 0.238 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 5.793608e-01 | 0.237 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 5.794932e-01 | 0.237 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 5.794932e-01 | 0.237 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 5.794932e-01 | 0.237 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 5.828435e-01 | 0.234 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 5.863054e-01 | 0.232 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 5.863054e-01 | 0.232 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.863054e-01 | 0.232 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 5.863054e-01 | 0.232 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 5.863054e-01 | 0.232 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 5.863054e-01 | 0.232 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 5.898649e-01 | 0.229 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 5.898649e-01 | 0.229 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 5.898649e-01 | 0.229 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 5.898649e-01 | 0.229 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 5.919328e-01 | 0.228 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 5.947126e-01 | 0.226 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 5.947126e-01 | 0.226 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 5.967385e-01 | 0.224 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 5.988406e-01 | 0.223 | 0 | 0 |
| Protein folding | R-HSA-391251 | 6.020395e-01 | 0.220 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 6.027962e-01 | 0.220 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 6.027962e-01 | 0.220 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.070049e-01 | 0.217 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 6.073426e-01 | 0.217 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 6.094214e-01 | 0.215 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 6.104212e-01 | 0.214 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 6.104212e-01 | 0.214 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 6.104212e-01 | 0.214 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 6.120550e-01 | 0.213 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.145617e-01 | 0.211 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 6.165776e-01 | 0.210 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 6.175979e-01 | 0.209 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 6.175979e-01 | 0.209 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 6.191220e-01 | 0.208 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 6.191220e-01 | 0.208 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 6.191220e-01 | 0.208 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 6.191220e-01 | 0.208 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 6.191220e-01 | 0.208 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 6.191220e-01 | 0.208 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 6.191220e-01 | 0.208 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 6.191220e-01 | 0.208 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 6.191220e-01 | 0.208 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 6.191220e-01 | 0.208 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 6.191220e-01 | 0.208 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 6.199643e-01 | 0.208 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 6.210035e-01 | 0.207 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 6.210035e-01 | 0.207 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 6.210035e-01 | 0.207 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 6.220942e-01 | 0.206 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 6.243693e-01 | 0.205 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 6.243693e-01 | 0.205 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 6.252985e-01 | 0.204 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 6.252985e-01 | 0.204 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 6.252985e-01 | 0.204 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 6.268966e-01 | 0.203 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 6.268966e-01 | 0.203 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.268966e-01 | 0.203 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 6.268966e-01 | 0.203 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 6.268966e-01 | 0.203 | 0 | 0 |
| Phase 1 - inactivation of fast Na+ channels | R-HSA-5576894 | 6.268966e-01 | 0.203 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 6.268966e-01 | 0.203 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 6.268966e-01 | 0.203 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 6.268966e-01 | 0.203 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.268966e-01 | 0.203 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 6.268966e-01 | 0.203 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 6.268966e-01 | 0.203 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.268966e-01 | 0.203 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 6.268966e-01 | 0.203 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.268966e-01 | 0.203 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.268966e-01 | 0.203 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.268966e-01 | 0.203 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.268966e-01 | 0.203 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 6.268966e-01 | 0.203 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 6.268966e-01 | 0.203 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 6.287627e-01 | 0.202 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 6.303661e-01 | 0.200 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 6.307812e-01 | 0.200 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 6.323654e-01 | 0.199 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 6.334095e-01 | 0.198 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 6.340523e-01 | 0.198 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.345337e-01 | 0.198 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.355820e-01 | 0.197 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 6.356641e-01 | 0.197 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 6.356641e-01 | 0.197 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 6.426853e-01 | 0.192 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 6.461058e-01 | 0.190 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 6.461058e-01 | 0.190 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 6.461058e-01 | 0.190 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 6.461058e-01 | 0.190 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 6.461058e-01 | 0.190 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 6.461058e-01 | 0.190 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 6.462147e-01 | 0.190 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 6.469727e-01 | 0.189 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 6.469727e-01 | 0.189 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 6.482428e-01 | 0.188 | 0 | 0 |
| Depurination | R-HSA-73927 | 6.496769e-01 | 0.187 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 6.496769e-01 | 0.187 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 6.498938e-01 | 0.187 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 6.498938e-01 | 0.187 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 6.498938e-01 | 0.187 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 6.498938e-01 | 0.187 | 0 | 0 |
| Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA | R-HSA-77310 | 6.498938e-01 | 0.187 | 0 | 0 |
| Beta oxidation of octanoyl-CoA to hexanoyl-CoA | R-HSA-77348 | 6.498938e-01 | 0.187 | 0 | 0 |
| Beta oxidation of hexanoyl-CoA to butanoyl-CoA | R-HSA-77350 | 6.498938e-01 | 0.187 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 6.498938e-01 | 0.187 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 6.513339e-01 | 0.186 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 6.516319e-01 | 0.186 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 6.516319e-01 | 0.186 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 6.516319e-01 | 0.186 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 6.532158e-01 | 0.185 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 6.532158e-01 | 0.185 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 6.571526e-01 | 0.182 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.586966e-01 | 0.181 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 6.654607e-01 | 0.177 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 6.677996e-01 | 0.175 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 6.677996e-01 | 0.175 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 6.677996e-01 | 0.175 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 6.683359e-01 | 0.175 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.683359e-01 | 0.175 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 6.683359e-01 | 0.175 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 6.700048e-01 | 0.174 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 6.700048e-01 | 0.174 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 6.701679e-01 | 0.174 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 6.701679e-01 | 0.174 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 6.701679e-01 | 0.174 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.701679e-01 | 0.174 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 6.701679e-01 | 0.174 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 6.701679e-01 | 0.174 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 6.701679e-01 | 0.174 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 6.701679e-01 | 0.174 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 6.701679e-01 | 0.174 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 6.701679e-01 | 0.174 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 6.701679e-01 | 0.174 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 6.701679e-01 | 0.174 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 6.701679e-01 | 0.174 | 0 | 0 |
| Defective factor VIII causes hemophilia A | R-HSA-9662001 | 6.701679e-01 | 0.174 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 6.701679e-01 | 0.174 | 0 | 0 |
| Metabolism of vitamin K | R-HSA-6806664 | 6.701679e-01 | 0.174 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 6.701679e-01 | 0.174 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 6.701679e-01 | 0.174 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 6.701679e-01 | 0.174 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 6.701679e-01 | 0.174 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 6.702378e-01 | 0.174 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 6.714082e-01 | 0.173 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 6.728806e-01 | 0.172 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 6.728806e-01 | 0.172 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 6.728806e-01 | 0.172 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 6.738144e-01 | 0.171 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 6.760312e-01 | 0.170 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 6.786536e-01 | 0.168 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 6.786536e-01 | 0.168 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.786536e-01 | 0.168 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 6.786536e-01 | 0.168 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 6.786536e-01 | 0.168 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.786536e-01 | 0.168 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 6.786536e-01 | 0.168 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 6.786536e-01 | 0.168 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.826819e-01 | 0.166 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 6.861860e-01 | 0.164 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 6.863300e-01 | 0.163 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 6.877670e-01 | 0.163 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 6.877670e-01 | 0.163 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 6.926977e-01 | 0.159 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 6.926977e-01 | 0.159 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 6.982727e-01 | 0.156 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 7.029566e-01 | 0.153 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 7.036508e-01 | 0.153 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 7.036508e-01 | 0.153 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 7.036508e-01 | 0.153 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 7.042834e-01 | 0.152 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 7.054542e-01 | 0.152 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 7.054542e-01 | 0.152 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 7.054542e-01 | 0.152 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 7.054542e-01 | 0.152 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 7.054542e-01 | 0.152 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 7.054542e-01 | 0.152 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 7.054542e-01 | 0.152 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 7.054542e-01 | 0.152 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 7.054542e-01 | 0.152 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.068694e-01 | 0.151 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 7.068694e-01 | 0.151 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 7.084230e-01 | 0.150 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 7.084230e-01 | 0.150 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 7.084230e-01 | 0.150 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 7.084230e-01 | 0.150 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 7.084230e-01 | 0.150 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 7.084230e-01 | 0.150 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 7.084230e-01 | 0.150 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 7.084230e-01 | 0.150 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 7.084230e-01 | 0.150 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 7.084230e-01 | 0.150 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 7.084230e-01 | 0.150 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 7.084230e-01 | 0.150 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 7.084230e-01 | 0.150 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 7.084230e-01 | 0.150 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 7.084230e-01 | 0.150 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 7.134913e-01 | 0.147 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 7.141923e-01 | 0.146 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.150781e-01 | 0.146 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 7.165453e-01 | 0.145 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 7.172904e-01 | 0.144 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 7.175505e-01 | 0.144 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 7.180218e-01 | 0.144 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 7.202938e-01 | 0.142 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 7.202938e-01 | 0.142 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 7.202938e-01 | 0.142 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 7.202938e-01 | 0.142 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 7.202938e-01 | 0.142 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.231201e-01 | 0.141 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 7.249872e-01 | 0.140 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 7.251072e-01 | 0.140 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.251072e-01 | 0.140 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 7.256241e-01 | 0.139 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 7.289140e-01 | 0.137 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 7.303631e-01 | 0.136 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 7.303631e-01 | 0.136 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 7.303631e-01 | 0.136 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 7.303631e-01 | 0.136 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 7.303631e-01 | 0.136 | 0 | 0 |
| Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA | R-HSA-77346 | 7.303631e-01 | 0.136 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 7.311488e-01 | 0.136 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 7.311488e-01 | 0.136 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 7.328362e-01 | 0.135 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 7.345049e-01 | 0.134 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 7.345049e-01 | 0.134 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 7.345049e-01 | 0.134 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 7.345049e-01 | 0.134 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 7.362583e-01 | 0.133 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 7.362583e-01 | 0.133 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 7.362583e-01 | 0.133 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.417673e-01 | 0.130 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 7.422431e-01 | 0.129 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 7.422431e-01 | 0.129 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 7.422431e-01 | 0.129 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.422431e-01 | 0.129 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 7.422431e-01 | 0.129 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 7.422431e-01 | 0.129 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 7.422431e-01 | 0.129 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 7.422431e-01 | 0.129 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.422431e-01 | 0.129 | 0 | 0 |
| Nucleotide salvage defects | R-HSA-9734207 | 7.422431e-01 | 0.129 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 7.422431e-01 | 0.129 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 7.422431e-01 | 0.129 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 7.422431e-01 | 0.129 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 7.424859e-01 | 0.129 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 7.424859e-01 | 0.129 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 7.424859e-01 | 0.129 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 7.424859e-01 | 0.129 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 7.428100e-01 | 0.129 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 7.436814e-01 | 0.129 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 7.470906e-01 | 0.127 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 7.470906e-01 | 0.127 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 7.515467e-01 | 0.124 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 7.515467e-01 | 0.124 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 7.515467e-01 | 0.124 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 7.534585e-01 | 0.123 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 7.534585e-01 | 0.123 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 7.534585e-01 | 0.123 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 7.534585e-01 | 0.123 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 7.536591e-01 | 0.123 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 7.536591e-01 | 0.123 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 7.536591e-01 | 0.123 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 7.536591e-01 | 0.123 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 7.536591e-01 | 0.123 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 7.542840e-01 | 0.122 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 7.581505e-01 | 0.120 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 7.590156e-01 | 0.120 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 7.590156e-01 | 0.120 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 7.607867e-01 | 0.119 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.648408e-01 | 0.116 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 7.661646e-01 | 0.116 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 7.661646e-01 | 0.116 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 7.661646e-01 | 0.116 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 7.716843e-01 | 0.113 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 7.716843e-01 | 0.113 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 7.721422e-01 | 0.112 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 7.721422e-01 | 0.112 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 7.721422e-01 | 0.112 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 7.721422e-01 | 0.112 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 7.721422e-01 | 0.112 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 7.721422e-01 | 0.112 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.721422e-01 | 0.112 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 7.721422e-01 | 0.112 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.721422e-01 | 0.112 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 7.721422e-01 | 0.112 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 7.721422e-01 | 0.112 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 7.721422e-01 | 0.112 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.721422e-01 | 0.112 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 7.721422e-01 | 0.112 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.721422e-01 | 0.112 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 7.739283e-01 | 0.111 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 7.739283e-01 | 0.111 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 7.745800e-01 | 0.111 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 7.748259e-01 | 0.111 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 7.748259e-01 | 0.111 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 7.748259e-01 | 0.111 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 7.748259e-01 | 0.111 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 7.748259e-01 | 0.111 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 7.752536e-01 | 0.111 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 7.801203e-01 | 0.108 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 7.801203e-01 | 0.108 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 7.801203e-01 | 0.108 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 7.801203e-01 | 0.108 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 7.801203e-01 | 0.108 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 7.842317e-01 | 0.106 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 7.853340e-01 | 0.105 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 7.865212e-01 | 0.104 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 7.886150e-01 | 0.103 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 7.886150e-01 | 0.103 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 7.886150e-01 | 0.103 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 7.895874e-01 | 0.103 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 7.895874e-01 | 0.103 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 7.895874e-01 | 0.103 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 7.895874e-01 | 0.103 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 7.896026e-01 | 0.103 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 7.896026e-01 | 0.103 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 7.923152e-01 | 0.101 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 7.927792e-01 | 0.101 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 7.934244e-01 | 0.100 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 7.936655e-01 | 0.100 | 0 | 0 |
| Erythrocytes take up carbon dioxide and release oxygen | R-HSA-1237044 | 7.945553e-01 | 0.100 | 0 | 0 |
| O2/CO2 exchange in erythrocytes | R-HSA-1480926 | 7.945553e-01 | 0.100 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 7.945553e-01 | 0.100 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 7.945553e-01 | 0.100 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 7.985746e-01 | 0.098 | 0 | 0 |
| OADH complex synthesizes glutaryl-CoA from 2-OA | R-HSA-9858328 | 7.985746e-01 | 0.098 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 7.985746e-01 | 0.098 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.985746e-01 | 0.098 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 7.985746e-01 | 0.098 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 7.985746e-01 | 0.098 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 7.985746e-01 | 0.098 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 7.985746e-01 | 0.098 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.985746e-01 | 0.098 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 7.985746e-01 | 0.098 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 7.985746e-01 | 0.098 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 7.985746e-01 | 0.098 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 7.985746e-01 | 0.098 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 8.044891e-01 | 0.094 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 8.060894e-01 | 0.094 | 0 | 0 |
| Immune System | R-HSA-168256 | 8.065085e-01 | 0.093 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 8.091473e-01 | 0.092 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 8.103242e-01 | 0.091 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 8.115520e-01 | 0.091 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 8.127392e-01 | 0.090 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 8.127392e-01 | 0.090 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 8.127392e-01 | 0.090 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 8.127392e-01 | 0.090 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 8.127392e-01 | 0.090 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 8.127392e-01 | 0.090 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 8.127392e-01 | 0.090 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 8.127392e-01 | 0.090 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.153676e-01 | 0.089 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 8.169712e-01 | 0.088 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 8.181298e-01 | 0.087 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 8.193474e-01 | 0.087 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 8.193474e-01 | 0.087 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 8.200517e-01 | 0.086 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 8.219421e-01 | 0.085 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 8.219421e-01 | 0.085 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 8.219421e-01 | 0.085 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 8.219421e-01 | 0.085 | 0 | 0 |
| Conjugation of benzoate with glycine | R-HSA-177135 | 8.219421e-01 | 0.085 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 8.219421e-01 | 0.085 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 8.219421e-01 | 0.085 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 8.219421e-01 | 0.085 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 8.219421e-01 | 0.085 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 8.219421e-01 | 0.085 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.241390e-01 | 0.084 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 8.254424e-01 | 0.083 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 8.294528e-01 | 0.081 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 8.294705e-01 | 0.081 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 8.294705e-01 | 0.081 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 8.294705e-01 | 0.081 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.294705e-01 | 0.081 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 8.294705e-01 | 0.081 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 8.294705e-01 | 0.081 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 8.294705e-01 | 0.081 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 8.295248e-01 | 0.081 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 8.295248e-01 | 0.081 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.295248e-01 | 0.081 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 8.295248e-01 | 0.081 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 8.295613e-01 | 0.081 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 8.295613e-01 | 0.081 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 8.315742e-01 | 0.080 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 8.332327e-01 | 0.079 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 8.332327e-01 | 0.079 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 8.361805e-01 | 0.078 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 8.404011e-01 | 0.076 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 8.413536e-01 | 0.075 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 8.413536e-01 | 0.075 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 8.414340e-01 | 0.075 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 8.415614e-01 | 0.075 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 8.415614e-01 | 0.075 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 8.425999e-01 | 0.074 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 8.425999e-01 | 0.074 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 8.425999e-01 | 0.074 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 8.425999e-01 | 0.074 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 8.425999e-01 | 0.074 | 0 | 0 |
| FMO oxidises nucleophiles | R-HSA-217271 | 8.425999e-01 | 0.074 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 8.425999e-01 | 0.074 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 8.425999e-01 | 0.074 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.425999e-01 | 0.074 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 8.425999e-01 | 0.074 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 8.425999e-01 | 0.074 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 8.448415e-01 | 0.073 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 8.461893e-01 | 0.073 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 8.461893e-01 | 0.073 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 8.510633e-01 | 0.070 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 8.524844e-01 | 0.069 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 8.524844e-01 | 0.069 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 8.524844e-01 | 0.069 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 8.524844e-01 | 0.069 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.525540e-01 | 0.069 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 8.527700e-01 | 0.069 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 8.582618e-01 | 0.066 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 8.582829e-01 | 0.066 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 8.589425e-01 | 0.066 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 8.589425e-01 | 0.066 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 8.589425e-01 | 0.066 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 8.600937e-01 | 0.065 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 8.603789e-01 | 0.065 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 8.603789e-01 | 0.065 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 8.608621e-01 | 0.065 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 8.608621e-01 | 0.065 | 0 | 0 |
| Beta oxidation of myristoyl-CoA to lauroyl-CoA | R-HSA-77285 | 8.608621e-01 | 0.065 | 0 | 0 |
| Beta oxidation of palmitoyl-CoA to myristoyl-CoA | R-HSA-77305 | 8.608621e-01 | 0.065 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 8.608621e-01 | 0.065 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 8.608621e-01 | 0.065 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.608621e-01 | 0.065 | 0 | 0 |
| Conjugation of salicylate with glycine | R-HSA-177128 | 8.608621e-01 | 0.065 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 8.608621e-01 | 0.065 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 8.608621e-01 | 0.065 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 8.608621e-01 | 0.065 | 0 | 0 |
| Erythrocytes take up oxygen and release carbon dioxide | R-HSA-1247673 | 8.608621e-01 | 0.065 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 8.608621e-01 | 0.065 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.608621e-01 | 0.065 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 8.615904e-01 | 0.065 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 8.624649e-01 | 0.064 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 8.629451e-01 | 0.064 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 8.629451e-01 | 0.064 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 8.638812e-01 | 0.064 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 8.639698e-01 | 0.064 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 8.639698e-01 | 0.064 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 8.686671e-01 | 0.061 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 8.694954e-01 | 0.061 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 8.694954e-01 | 0.061 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 8.694954e-01 | 0.061 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 8.706802e-01 | 0.060 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 8.718613e-01 | 0.060 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 8.718613e-01 | 0.060 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 8.718613e-01 | 0.060 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 8.718613e-01 | 0.060 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.770064e-01 | 0.057 | 0 | 0 |
| OGDH complex synthesizes succinyl-CoA from 2-OG | R-HSA-9853506 | 8.770064e-01 | 0.057 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 8.770064e-01 | 0.057 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 8.770064e-01 | 0.057 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 8.770064e-01 | 0.057 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 8.770064e-01 | 0.057 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.770064e-01 | 0.057 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 8.777874e-01 | 0.057 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.799349e-01 | 0.056 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 8.799349e-01 | 0.056 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 8.819690e-01 | 0.055 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.836823e-01 | 0.054 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 8.836823e-01 | 0.054 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 8.836823e-01 | 0.054 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.836823e-01 | 0.054 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 8.841142e-01 | 0.053 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 8.841142e-01 | 0.053 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 8.843168e-01 | 0.053 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 8.859860e-01 | 0.053 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 8.896245e-01 | 0.051 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 8.896245e-01 | 0.051 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 8.905893e-01 | 0.050 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 8.905893e-01 | 0.050 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 8.912444e-01 | 0.050 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 8.912783e-01 | 0.050 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 8.912783e-01 | 0.050 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 8.912783e-01 | 0.050 | 0 | 0 |
| Synthesis of IPs in the nucleus | R-HSA-1855191 | 8.912783e-01 | 0.050 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 8.912783e-01 | 0.050 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.912783e-01 | 0.050 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 8.912783e-01 | 0.050 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 8.912783e-01 | 0.050 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 8.912783e-01 | 0.050 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.912783e-01 | 0.050 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 8.912783e-01 | 0.050 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.912783e-01 | 0.050 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.912783e-01 | 0.050 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 8.912783e-01 | 0.050 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.912783e-01 | 0.050 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 8.935745e-01 | 0.049 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 8.944863e-01 | 0.048 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 8.944863e-01 | 0.048 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 8.944863e-01 | 0.048 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.944863e-01 | 0.048 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 8.944863e-01 | 0.048 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 8.986076e-01 | 0.046 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 8.986076e-01 | 0.046 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.017001e-01 | 0.045 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.024199e-01 | 0.045 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 9.038949e-01 | 0.044 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 9.038949e-01 | 0.044 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 9.038949e-01 | 0.044 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 9.038949e-01 | 0.044 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 9.038949e-01 | 0.044 | 0 | 0 |
| Beta oxidation of butanoyl-CoA to acetyl-CoA | R-HSA-77352 | 9.038949e-01 | 0.044 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 9.038949e-01 | 0.044 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 9.038949e-01 | 0.044 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 9.038949e-01 | 0.044 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 9.038949e-01 | 0.044 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.043500e-01 | 0.044 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 9.043500e-01 | 0.044 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 9.043500e-01 | 0.044 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 9.043500e-01 | 0.044 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 9.043500e-01 | 0.044 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 9.061880e-01 | 0.043 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.069264e-01 | 0.042 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 9.118787e-01 | 0.040 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 9.132218e-01 | 0.039 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 9.133462e-01 | 0.039 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.133462e-01 | 0.039 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.133462e-01 | 0.039 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.133462e-01 | 0.039 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.145041e-01 | 0.039 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 9.146218e-01 | 0.039 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 9.150480e-01 | 0.039 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 9.150480e-01 | 0.039 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 9.150480e-01 | 0.039 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 9.150480e-01 | 0.039 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 9.150480e-01 | 0.039 | 0 | 0 |
| Mitochondrial Uncoupling | R-HSA-166187 | 9.150480e-01 | 0.039 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 9.150480e-01 | 0.039 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 9.150480e-01 | 0.039 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 9.171621e-01 | 0.038 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.190335e-01 | 0.037 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.197814e-01 | 0.036 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.205262e-01 | 0.036 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.215432e-01 | 0.035 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.217332e-01 | 0.035 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.217332e-01 | 0.035 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.226300e-01 | 0.035 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 9.249073e-01 | 0.034 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.249073e-01 | 0.034 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.249073e-01 | 0.034 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 9.249073e-01 | 0.034 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 9.249073e-01 | 0.034 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of unsaturated fatty acids | R-HSA-77288 | 9.249073e-01 | 0.034 | 0 | 0 |
| Vitamin B6 activation to pyridoxal phosphate | R-HSA-964975 | 9.249073e-01 | 0.034 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 9.249073e-01 | 0.034 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 9.249073e-01 | 0.034 | 0 | 0 |
| Formation of xylulose-5-phosphate | R-HSA-5661270 | 9.249073e-01 | 0.034 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 9.249073e-01 | 0.034 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.249073e-01 | 0.034 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 9.249073e-01 | 0.034 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 9.249073e-01 | 0.034 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 9.255162e-01 | 0.034 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.258929e-01 | 0.033 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 9.261190e-01 | 0.033 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.273407e-01 | 0.033 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.277787e-01 | 0.033 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 9.282987e-01 | 0.032 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 9.282987e-01 | 0.032 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.290055e-01 | 0.032 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.313697e-01 | 0.031 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.313829e-01 | 0.031 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.315817e-01 | 0.031 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.336230e-01 | 0.030 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 9.336230e-01 | 0.030 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 9.336230e-01 | 0.030 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.336230e-01 | 0.030 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 9.357930e-01 | 0.029 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.357930e-01 | 0.029 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.363548e-01 | 0.029 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.375244e-01 | 0.028 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 9.413275e-01 | 0.026 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.413275e-01 | 0.026 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 9.413275e-01 | 0.026 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.413275e-01 | 0.026 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.413275e-01 | 0.026 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 9.414559e-01 | 0.026 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.445240e-01 | 0.025 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 9.450734e-01 | 0.025 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.450734e-01 | 0.025 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.452201e-01 | 0.024 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.469012e-01 | 0.024 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 9.481381e-01 | 0.023 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 9.481381e-01 | 0.023 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 9.481381e-01 | 0.023 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.481381e-01 | 0.023 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 9.481381e-01 | 0.023 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 9.481381e-01 | 0.023 | 0 | 0 |
| Conjugation of carboxylic acids | R-HSA-159424 | 9.481381e-01 | 0.023 | 0 | 0 |
| Amino Acid conjugation | R-HSA-156587 | 9.481381e-01 | 0.023 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.481381e-01 | 0.023 | 0 | 0 |
| Transport of nucleotide sugars | R-HSA-727802 | 9.481381e-01 | 0.023 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 9.481381e-01 | 0.023 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.481381e-01 | 0.023 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.486010e-01 | 0.023 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.486010e-01 | 0.023 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.486010e-01 | 0.023 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.492562e-01 | 0.023 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.514432e-01 | 0.022 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.516235e-01 | 0.022 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.526485e-01 | 0.021 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.529881e-01 | 0.021 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.541585e-01 | 0.020 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 9.541585e-01 | 0.020 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 9.541585e-01 | 0.020 | 0 | 0 |
| Melanin biosynthesis | R-HSA-5662702 | 9.541585e-01 | 0.020 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.541585e-01 | 0.020 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 9.541585e-01 | 0.020 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 9.541585e-01 | 0.020 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 9.564833e-01 | 0.019 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 9.572593e-01 | 0.019 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.572593e-01 | 0.019 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.572593e-01 | 0.019 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 9.572593e-01 | 0.019 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.578256e-01 | 0.019 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 9.594803e-01 | 0.018 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.594803e-01 | 0.018 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 9.594803e-01 | 0.018 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.594803e-01 | 0.018 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 9.594803e-01 | 0.018 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 9.594803e-01 | 0.018 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.594803e-01 | 0.018 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 9.594803e-01 | 0.018 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.594803e-01 | 0.018 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.609266e-01 | 0.017 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 9.614381e-01 | 0.017 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.614381e-01 | 0.017 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.614381e-01 | 0.017 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 9.618015e-01 | 0.017 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.618015e-01 | 0.017 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.627358e-01 | 0.016 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.629616e-01 | 0.016 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.638047e-01 | 0.016 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 9.641846e-01 | 0.016 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.641846e-01 | 0.016 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.641846e-01 | 0.016 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.641846e-01 | 0.016 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.646272e-01 | 0.016 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.652231e-01 | 0.015 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.668337e-01 | 0.015 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.668337e-01 | 0.015 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 9.672087e-01 | 0.014 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.675046e-01 | 0.014 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.680922e-01 | 0.014 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 9.683430e-01 | 0.014 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 9.683430e-01 | 0.014 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.683430e-01 | 0.014 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 9.683430e-01 | 0.014 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 9.683430e-01 | 0.014 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.686432e-01 | 0.014 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 9.710641e-01 | 0.013 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.715090e-01 | 0.013 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.717489e-01 | 0.012 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.717489e-01 | 0.012 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.717489e-01 | 0.012 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 9.720187e-01 | 0.012 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 9.720187e-01 | 0.012 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 9.720187e-01 | 0.012 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 9.734965e-01 | 0.012 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 9.734965e-01 | 0.012 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.738213e-01 | 0.012 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.745516e-01 | 0.011 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.745516e-01 | 0.011 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.752679e-01 | 0.011 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 9.752679e-01 | 0.011 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 9.752679e-01 | 0.011 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.752679e-01 | 0.011 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 9.752679e-01 | 0.011 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 9.753470e-01 | 0.011 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.767784e-01 | 0.010 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 9.770846e-01 | 0.010 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.776383e-01 | 0.010 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 9.781399e-01 | 0.010 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.781399e-01 | 0.010 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.781399e-01 | 0.010 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.787627e-01 | 0.009 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.793727e-01 | 0.009 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.804345e-01 | 0.009 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.804345e-01 | 0.009 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.806786e-01 | 0.008 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.806786e-01 | 0.008 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 9.806786e-01 | 0.008 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 9.814386e-01 | 0.008 | 0 | 0 |
| Translation | R-HSA-72766 | 9.827209e-01 | 0.008 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 9.829226e-01 | 0.007 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 9.829226e-01 | 0.007 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.829226e-01 | 0.007 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 9.829226e-01 | 0.007 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.829226e-01 | 0.007 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.829226e-01 | 0.007 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.833030e-01 | 0.007 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.837887e-01 | 0.007 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.843695e-01 | 0.007 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.849061e-01 | 0.007 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.857733e-01 | 0.006 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.864655e-01 | 0.006 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.864655e-01 | 0.006 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 9.866593e-01 | 0.006 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.870884e-01 | 0.006 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.875966e-01 | 0.005 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.878683e-01 | 0.005 | 0 | 0 |
| mitochondrial fatty acid beta-oxidation of saturated fatty acids | R-HSA-77286 | 9.890999e-01 | 0.005 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.895659e-01 | 0.005 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.895787e-01 | 0.005 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.895787e-01 | 0.005 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.898858e-01 | 0.004 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.898858e-01 | 0.004 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.902092e-01 | 0.004 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.907893e-01 | 0.004 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 9.907893e-01 | 0.004 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.911766e-01 | 0.004 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.912079e-01 | 0.004 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 9.918594e-01 | 0.004 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.920559e-01 | 0.003 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.921068e-01 | 0.003 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 9.928053e-01 | 0.003 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.928053e-01 | 0.003 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.936412e-01 | 0.003 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 9.936412e-01 | 0.003 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.936412e-01 | 0.003 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.936412e-01 | 0.003 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.937608e-01 | 0.003 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.942971e-01 | 0.002 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.942971e-01 | 0.002 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.944025e-01 | 0.002 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.948519e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.949335e-01 | 0.002 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.950009e-01 | 0.002 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 9.950332e-01 | 0.002 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.950332e-01 | 0.002 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.954135e-01 | 0.002 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.954155e-01 | 0.002 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 9.956104e-01 | 0.002 | 0 | 0 |
| Ubiquinol biosynthesis | R-HSA-2142789 | 9.956104e-01 | 0.002 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 9.956104e-01 | 0.002 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.956104e-01 | 0.002 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.958110e-01 | 0.002 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.958160e-01 | 0.002 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.961206e-01 | 0.002 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.961206e-01 | 0.002 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.964440e-01 | 0.002 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 9.965715e-01 | 0.001 | 0 | 0 |
| Diseases associated with N-glycosylation of proteins | R-HSA-3781860 | 9.965715e-01 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.966091e-01 | 0.001 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.966994e-01 | 0.001 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.969573e-01 | 0.001 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 9.969700e-01 | 0.001 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.969700e-01 | 0.001 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.970675e-01 | 0.001 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.971797e-01 | 0.001 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 9.973222e-01 | 0.001 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.973222e-01 | 0.001 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.976335e-01 | 0.001 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.976335e-01 | 0.001 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.978743e-01 | 0.001 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.979389e-01 | 0.001 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.980969e-01 | 0.001 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.980969e-01 | 0.001 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 9.981518e-01 | 0.001 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.981518e-01 | 0.001 | 0 | 0 |
| Methylation | R-HSA-156581 | 9.983667e-01 | 0.001 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.983667e-01 | 0.001 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.984501e-01 | 0.001 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.985227e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.985535e-01 | 0.001 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.985566e-01 | 0.001 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 9.985566e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.985595e-01 | 0.001 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.986926e-01 | 0.001 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.987282e-01 | 0.001 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.987282e-01 | 0.001 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.988469e-01 | 0.001 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.989240e-01 | 0.000 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.990038e-01 | 0.000 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.991197e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.991509e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.993020e-01 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.993126e-01 | 0.000 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 9.995257e-01 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 9.995548e-01 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 9.995808e-01 | 0.000 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.995808e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.996022e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.997166e-01 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.997399e-01 | 0.000 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.997444e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.997700e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.997983e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.998005e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.998158e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.998206e-01 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.998258e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.998389e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.999050e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.999050e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999129e-01 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.999176e-01 | 0.000 | 0 | 0 |
| Classical antibody-mediated complement activation | R-HSA-173623 | 9.999190e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999355e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.999421e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.999421e-01 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.999489e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999548e-01 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.999548e-01 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999584e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999634e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999653e-01 | 0.000 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.999757e-01 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.999757e-01 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.999785e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.999818e-01 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 9.999920e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999928e-01 | 0.000 | 0 | 0 |
| Creation of C4 and C2 activators | R-HSA-166786 | 9.999928e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999931e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.999972e-01 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 9.999975e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999977e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999982e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999986e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999988e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999988e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999989e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999992e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999992e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999994e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999995e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.999997e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999997e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999997e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999997e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999997e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999998e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999998e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Macroautophagy | R-HSA-1632852 | 0.000009 | 5.033 | 1 | 1 |
| Autophagy | R-HSA-9612973 | 0.000030 | 4.523 | 1 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.000048 | 4.323 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.000105 | 3.980 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.000097 | 4.014 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.000132 | 3.880 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.000211 | 3.676 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.000229 | 3.640 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.000351 | 3.455 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 0.000418 | 3.379 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.000603 | 3.220 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.000603 | 3.220 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.000895 | 3.048 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.000902 | 3.045 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.001184 | 2.927 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.001184 | 2.927 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.001184 | 2.927 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.001184 | 2.927 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.001147 | 2.940 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.001457 | 2.836 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.001492 | 2.826 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.001492 | 2.826 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.001492 | 2.826 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.001492 | 2.826 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.001355 | 2.868 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.001619 | 2.791 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.001700 | 2.770 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.001938 | 2.713 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.002170 | 2.664 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.002424 | 2.616 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.002507 | 2.601 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.002668 | 2.574 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.002797 | 2.553 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.002956 | 2.529 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.003445 | 2.463 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.003549 | 2.450 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.003549 | 2.450 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.003545 | 2.450 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.003907 | 2.408 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.004234 | 2.373 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 0.004681 | 2.330 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.004831 | 2.316 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.005680 | 2.246 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.005660 | 2.247 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.005557 | 2.255 | 1 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.005722 | 2.242 | 1 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 0.005885 | 2.230 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.006021 | 2.220 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.006525 | 2.185 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.007152 | 2.146 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.007152 | 2.146 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.007301 | 2.137 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.007358 | 2.133 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.007947 | 2.100 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.007947 | 2.100 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.008084 | 2.092 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.008406 | 2.075 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 0.009283 | 2.032 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.009350 | 2.029 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.009460 | 2.024 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.009839 | 2.007 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.010936 | 1.961 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.010708 | 1.970 | 1 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.010648 | 1.973 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.010823 | 1.966 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.011068 | 1.956 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.011807 | 1.928 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.012988 | 1.886 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.013087 | 1.883 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 0.013755 | 1.862 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.015923 | 1.798 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.016940 | 1.771 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.016940 | 1.771 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.016305 | 1.788 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.019038 | 1.720 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.018189 | 1.740 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.019038 | 1.720 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.019578 | 1.708 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.019169 | 1.717 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.020080 | 1.697 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.020230 | 1.694 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.020877 | 1.680 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.021041 | 1.677 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.022459 | 1.649 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.023353 | 1.632 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.023522 | 1.629 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 0.023522 | 1.629 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.023810 | 1.623 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.025434 | 1.595 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.025586 | 1.592 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.026288 | 1.580 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.026288 | 1.580 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.026288 | 1.580 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.026662 | 1.574 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.028071 | 1.552 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.030778 | 1.512 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.031725 | 1.499 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.031750 | 1.498 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.030323 | 1.518 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 0.030329 | 1.518 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.029787 | 1.526 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.031861 | 1.497 | 1 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.032746 | 1.485 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.033727 | 1.472 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 0.034472 | 1.463 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.035598 | 1.449 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.036974 | 1.432 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 0.037407 | 1.427 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.038725 | 1.412 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.038725 | 1.412 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.042455 | 1.372 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.040626 | 1.391 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.041181 | 1.385 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.042712 | 1.369 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.043114 | 1.365 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.046517 | 1.332 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.045656 | 1.341 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.045542 | 1.342 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.046474 | 1.333 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.046474 | 1.333 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.046474 | 1.333 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.046474 | 1.333 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.047511 | 1.323 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.046474 | 1.333 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.048200 | 1.317 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.048219 | 1.317 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 0.048219 | 1.317 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.050389 | 1.298 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.051850 | 1.285 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.062313 | 1.205 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 0.062313 | 1.205 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.062313 | 1.205 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.062313 | 1.205 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.062313 | 1.205 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.062313 | 1.205 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.053861 | 1.269 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.052382 | 1.281 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.060079 | 1.221 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.057611 | 1.239 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.062028 | 1.207 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.059001 | 1.229 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.060452 | 1.219 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.052382 | 1.281 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.059001 | 1.229 | 1 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.056336 | 1.249 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.058269 | 1.235 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.055281 | 1.257 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 0.095823 | 1.019 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 0.095823 | 1.019 | 0 | 0 |
| Deletions in the AMER1 gene destabilize the destruction complex | R-HSA-5467343 | 0.095823 | 1.019 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 0.095823 | 1.019 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.095823 | 1.019 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.182468 | 0.739 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.182468 | 0.739 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.182468 | 0.739 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.182468 | 0.739 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 0.182468 | 0.739 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 0.182468 | 0.739 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 0.182468 | 0.739 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 0.182468 | 0.739 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.182468 | 0.739 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 0.182468 | 0.739 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.091284 | 1.040 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.063887 | 1.195 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 0.123315 | 0.909 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 0.123315 | 0.909 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 0.123315 | 0.909 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 0.123315 | 0.909 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 0.260816 | 0.584 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 0.260816 | 0.584 | 0 | 0 |
| t(4;14) translocations of FGFR3 | R-HSA-2033515 | 0.260816 | 0.584 | 0 | 0 |
| Signaling by FGFR3 fusions in cancer | R-HSA-8853334 | 0.260816 | 0.584 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 0.260816 | 0.584 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 0.260816 | 0.584 | 0 | 0 |
| Defective SLC9A9 causes autism 16 (AUTS16) | R-HSA-5619052 | 0.260816 | 0.584 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5660724 | 0.260816 | 0.584 | 0 | 0 |
| XAV939 stabilizes AXIN | R-HSA-5545619 | 0.260816 | 0.584 | 0 | 0 |
| Defective CD320 causes MMATC | R-HSA-3359485 | 0.260816 | 0.584 | 0 | 0 |
| Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS) | R-HSA-5619081 | 0.260816 | 0.584 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 0.260816 | 0.584 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 0.260816 | 0.584 | 0 | 0 |
| Defective HK1 causes hexokinase deficiency (HK deficiency) | R-HSA-5619056 | 0.260816 | 0.584 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 0.260816 | 0.584 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.081586 | 1.088 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.157552 | 0.803 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 0.157552 | 0.803 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 0.157552 | 0.803 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 0.157552 | 0.803 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 0.157552 | 0.803 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.101137 | 0.995 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.101137 | 0.995 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.101137 | 0.995 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.066930 | 1.174 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.122345 | 0.912 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.122345 | 0.912 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.193281 | 0.714 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.193281 | 0.714 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 0.331659 | 0.479 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 0.331659 | 0.479 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 0.331659 | 0.479 | 0 | 0 |
| Glycogen storage disease type II (GAA) | R-HSA-5357609 | 0.331659 | 0.479 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 0.331659 | 0.479 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 0.331659 | 0.479 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 0.094943 | 1.023 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.094943 | 1.023 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 0.145004 | 0.839 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.074103 | 1.130 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 0.229902 | 0.638 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.168904 | 0.772 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.168904 | 0.772 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.168904 | 0.772 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.168904 | 0.772 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 0.127557 | 0.894 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.127557 | 0.894 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 0.145397 | 0.837 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.193836 | 0.713 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.193836 | 0.713 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.193836 | 0.713 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.193836 | 0.713 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.266915 | 0.574 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 0.266915 | 0.574 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.266915 | 0.574 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 0.266915 | 0.574 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.266915 | 0.574 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.266915 | 0.574 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 0.395716 | 0.403 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 0.395716 | 0.403 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 0.395716 | 0.403 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 0.395716 | 0.403 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.395716 | 0.403 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 0.395716 | 0.403 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 0.395716 | 0.403 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 0.395716 | 0.403 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.075230 | 1.124 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.125102 | 0.903 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.219600 | 0.658 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.219600 | 0.658 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.219600 | 0.658 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.219600 | 0.658 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.219600 | 0.658 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.119816 | 0.921 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.303910 | 0.517 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 0.303910 | 0.517 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 0.303910 | 0.517 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.132384 | 0.878 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 0.246001 | 0.609 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 0.246001 | 0.609 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.246001 | 0.609 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.113465 | 0.945 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.203959 | 0.690 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.145551 | 0.837 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.159287 | 0.798 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.340550 | 0.468 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 0.340550 | 0.468 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.340550 | 0.468 | 0 | 0 |
| Hypusine synthesis from eIF5A-lysine | R-HSA-204626 | 0.340550 | 0.468 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.340550 | 0.468 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 0.453637 | 0.343 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 0.453637 | 0.343 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.453637 | 0.343 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.453637 | 0.343 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 0.453637 | 0.343 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.076097 | 1.119 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.173559 | 0.761 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.173559 | 0.761 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.246233 | 0.609 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.299994 | 0.523 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.203572 | 0.691 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.203572 | 0.691 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.203572 | 0.691 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 0.376564 | 0.424 | 1 | 1 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.376564 | 0.424 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.241663 | 0.617 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.219238 | 0.659 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.219238 | 0.659 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.327259 | 0.485 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.327259 | 0.485 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.144519 | 0.840 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.144519 | 0.840 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.290185 | 0.537 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.290185 | 0.537 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.154126 | 0.812 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.118721 | 0.925 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.251690 | 0.599 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.312557 | 0.505 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.354507 | 0.450 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 0.411735 | 0.385 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.506010 | 0.296 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.506010 | 0.296 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 0.506010 | 0.296 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.184770 | 0.733 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.184770 | 0.733 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.160283 | 0.795 | 1 | 1 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.202847 | 0.693 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.357656 | 0.447 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 0.445895 | 0.351 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 0.445895 | 0.351 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.445895 | 0.351 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.288630 | 0.540 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.288630 | 0.540 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.337487 | 0.472 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.275888 | 0.559 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.065889 | 1.181 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.408448 | 0.389 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 0.408448 | 0.389 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.402702 | 0.395 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.434922 | 0.362 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 0.434922 | 0.362 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.434922 | 0.362 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.434922 | 0.362 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 0.478914 | 0.320 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.478914 | 0.320 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.478914 | 0.320 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 0.553365 | 0.257 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 0.553365 | 0.257 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 0.553365 | 0.257 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 0.553365 | 0.257 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 0.553365 | 0.257 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.553365 | 0.257 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 0.553365 | 0.257 | 0 | 0 |
| Phase 1 - inactivation of fast Na+ channels | R-HSA-5576894 | 0.553365 | 0.257 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.425026 | 0.372 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.460941 | 0.336 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.416160 | 0.381 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 0.510697 | 0.292 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.510697 | 0.292 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.400712 | 0.397 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.435679 | 0.361 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 0.486427 | 0.313 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.416909 | 0.380 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.468968 | 0.329 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.468968 | 0.329 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.429670 | 0.367 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.511316 | 0.291 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.511316 | 0.291 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 0.541178 | 0.267 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 0.541178 | 0.267 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 0.596183 | 0.225 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 0.596183 | 0.225 | 0 | 0 |
| Defective B4GALT1 causes B4GALT1-CDG (CDG-2d) | R-HSA-3656244 | 0.596183 | 0.225 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.596183 | 0.225 | 0 | 0 |
| Defective CHST6 causes MCDC1 | R-HSA-3656225 | 0.596183 | 0.225 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 0.596183 | 0.225 | 0 | 0 |
| Defective ST3GAL3 causes MCT12 and EIEE15 | R-HSA-3656243 | 0.596183 | 0.225 | 0 | 0 |
| Defective CHST3 causes SEDCJD | R-HSA-3595172 | 0.596183 | 0.225 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.397222 | 0.401 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.535551 | 0.271 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.532346 | 0.274 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 0.570314 | 0.244 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.570314 | 0.244 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 0.570314 | 0.244 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 0.570314 | 0.244 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 0.570314 | 0.244 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.570314 | 0.244 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.559087 | 0.253 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.559087 | 0.253 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.491527 | 0.308 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.552629 | 0.258 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 0.598082 | 0.223 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 0.634898 | 0.197 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 0.634898 | 0.197 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 0.634898 | 0.197 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.634898 | 0.197 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 0.634898 | 0.197 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.634898 | 0.197 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 0.634898 | 0.197 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 0.634898 | 0.197 | 0 | 0 |
| Defective CHSY1 causes TPBS | R-HSA-3595177 | 0.634898 | 0.197 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 0.634898 | 0.197 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.577554 | 0.238 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.580379 | 0.236 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 0.603925 | 0.219 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 0.603925 | 0.219 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 0.603925 | 0.219 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 0.603925 | 0.219 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.596571 | 0.224 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 0.624479 | 0.204 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 0.624479 | 0.204 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 0.624479 | 0.204 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.623558 | 0.205 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.081988 | 1.086 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.097682 | 1.010 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.147686 | 0.831 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.492688 | 0.307 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.188333 | 0.725 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.103089 | 0.987 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.268047 | 0.572 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.268047 | 0.572 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.511617 | 0.291 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.234561 | 0.630 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.208175 | 0.682 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.183694 | 0.736 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.183694 | 0.736 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.548389 | 0.261 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.199812 | 0.699 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.408448 | 0.389 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.402702 | 0.395 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.111106 | 0.954 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.299994 | 0.523 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.159032 | 0.799 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 0.376564 | 0.424 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.340346 | 0.468 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.340346 | 0.468 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.386869 | 0.412 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.527155 | 0.278 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.511316 | 0.291 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.340346 | 0.468 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 0.246001 | 0.609 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.223111 | 0.651 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.506085 | 0.296 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 0.193836 | 0.713 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.107871 | 0.967 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.299675 | 0.523 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.486427 | 0.313 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 0.634898 | 0.197 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.603925 | 0.219 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.354507 | 0.450 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.445895 | 0.351 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.552629 | 0.258 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.617130 | 0.210 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 0.080328 | 1.095 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 0.272855 | 0.564 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.474232 | 0.324 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.535551 | 0.271 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.577554 | 0.238 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.288630 | 0.540 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.205580 | 0.687 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.536645 | 0.270 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 0.624479 | 0.204 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.182758 | 0.738 | 1 | 1 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 0.474232 | 0.324 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.596571 | 0.224 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.129547 | 0.888 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.273158 | 0.564 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.434922 | 0.362 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.443315 | 0.353 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.132384 | 0.878 | 0 | 0 |
| Formation of lateral plate mesoderm | R-HSA-9758920 | 0.193281 | 0.714 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 0.127557 | 0.894 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.111106 | 0.954 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.147473 | 0.831 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.555488 | 0.255 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 0.312557 | 0.505 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.164965 | 0.783 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.319275 | 0.496 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.110711 | 0.956 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.552629 | 0.258 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.558178 | 0.253 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.077038 | 1.113 | 1 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 0.145397 | 0.837 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.117645 | 0.929 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 0.357148 | 0.447 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.123315 | 0.909 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.193836 | 0.713 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.219600 | 0.658 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 0.303910 | 0.517 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.171494 | 0.766 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 0.453637 | 0.343 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.246233 | 0.609 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.188333 | 0.725 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.087492 | 1.058 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.167636 | 0.776 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.235291 | 0.628 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.354507 | 0.450 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.445895 | 0.351 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.233543 | 0.632 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 0.434922 | 0.362 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.425026 | 0.372 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.223120 | 0.651 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.328753 | 0.483 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.481074 | 0.318 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 0.535551 | 0.271 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.399241 | 0.399 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.455663 | 0.341 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.334026 | 0.476 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.347667 | 0.459 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.065805 | 1.182 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.085574 | 1.068 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.203959 | 0.690 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.490477 | 0.309 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.113691 | 0.944 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.502152 | 0.299 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.502152 | 0.299 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.219600 | 0.658 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.116389 | 0.934 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.246233 | 0.609 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.376564 | 0.424 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.241663 | 0.617 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 0.381609 | 0.418 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.372724 | 0.429 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.443728 | 0.353 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 0.598082 | 0.223 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 0.478914 | 0.320 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.587570 | 0.231 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.122345 | 0.912 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 0.145004 | 0.839 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.110711 | 0.956 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.107871 | 0.967 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 0.376564 | 0.424 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 0.411735 | 0.385 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 0.506010 | 0.296 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 0.506010 | 0.296 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 0.506010 | 0.296 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 0.445895 | 0.351 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.478914 | 0.320 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 0.553365 | 0.257 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.242545 | 0.615 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.408111 | 0.389 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.393840 | 0.405 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.481074 | 0.318 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 0.570314 | 0.244 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 0.572435 | 0.242 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.598082 | 0.223 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.598082 | 0.223 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 0.634898 | 0.197 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 0.624479 | 0.204 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.136870 | 0.864 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.205580 | 0.687 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.205580 | 0.687 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.468968 | 0.329 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.087734 | 1.057 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 0.063527 | 1.197 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 0.380222 | 0.420 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 0.510697 | 0.292 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.313576 | 0.504 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.570314 | 0.244 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.581888 | 0.235 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.402702 | 0.395 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.396534 | 0.402 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.136523 | 0.865 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.548389 | 0.261 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.110711 | 0.956 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 0.229902 | 0.638 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.127557 | 0.894 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 0.246001 | 0.609 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 0.272855 | 0.564 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 0.453637 | 0.343 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 0.453637 | 0.343 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 0.453637 | 0.343 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.299994 | 0.523 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.069703 | 1.157 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.096192 | 1.017 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.220000 | 0.658 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.384504 | 0.415 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.449165 | 0.348 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.512452 | 0.290 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.552629 | 0.258 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.190067 | 0.721 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.429670 | 0.367 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.600527 | 0.221 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.183443 | 0.736 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.438909 | 0.358 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.460941 | 0.336 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.511617 | 0.291 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.210219 | 0.677 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.089693 | 1.047 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.229902 | 0.638 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.229902 | 0.638 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.106809 | 0.971 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.106809 | 0.971 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.434922 | 0.362 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.390423 | 0.408 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.447133 | 0.350 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 0.532346 | 0.274 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.074103 | 1.130 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.213941 | 0.670 | 1 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.086224 | 1.064 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 0.598082 | 0.223 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.341788 | 0.466 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.225956 | 0.646 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.380222 | 0.420 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.511316 | 0.291 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.438182 | 0.358 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.342302 | 0.466 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.617130 | 0.210 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.065805 | 1.182 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.228228 | 0.642 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.481692 | 0.317 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.453857 | 0.343 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.300736 | 0.522 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.157884 | 0.802 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.181249 | 0.742 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.603659 | 0.219 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.592155 | 0.228 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.423910 | 0.373 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.294215 | 0.531 | 0 | 0 |
| SDK interactions | R-HSA-373756 | 0.182468 | 0.739 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 0.123315 | 0.909 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 0.260816 | 0.584 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.157552 | 0.803 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.193281 | 0.714 | 0 | 0 |
| Proton/oligopeptide cotransporters | R-HSA-427975 | 0.193281 | 0.714 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 0.193281 | 0.714 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 0.331659 | 0.479 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.145397 | 0.837 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.193836 | 0.713 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.266915 | 0.574 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 0.395716 | 0.403 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.395716 | 0.403 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.219600 | 0.658 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 0.303910 | 0.517 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.246001 | 0.609 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.246001 | 0.609 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.106809 | 0.971 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 0.272855 | 0.564 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 0.272855 | 0.564 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.340550 | 0.468 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.376564 | 0.424 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 0.506010 | 0.296 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.285362 | 0.545 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.285362 | 0.545 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.302553 | 0.519 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 0.445895 | 0.351 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.408448 | 0.389 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 0.408448 | 0.389 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.265421 | 0.576 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.277641 | 0.557 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 0.478914 | 0.320 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 0.478914 | 0.320 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 0.553365 | 0.257 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 0.553365 | 0.257 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.553365 | 0.257 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.393840 | 0.405 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.326542 | 0.486 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.443315 | 0.353 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 0.596183 | 0.225 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 0.596183 | 0.225 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.457133 | 0.340 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.528893 | 0.277 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 0.598082 | 0.223 | 0 | 0 |
| Opsins | R-HSA-419771 | 0.634898 | 0.197 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.624479 | 0.204 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.399372 | 0.399 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.206935 | 0.684 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.457133 | 0.340 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.169356 | 0.771 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.619453 | 0.208 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.420503 | 0.376 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.408448 | 0.389 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.434922 | 0.362 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.478076 | 0.321 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.625179 | 0.204 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.199710 | 0.700 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 0.570314 | 0.244 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.197624 | 0.704 | 1 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.570314 | 0.244 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.581888 | 0.235 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.401491 | 0.396 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 0.634898 | 0.197 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.070478 | 1.152 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.454470 | 0.342 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.150925 | 0.821 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.174262 | 0.759 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.257914 | 0.589 | 1 | 1 |
| Long-term potentiation | R-HSA-9620244 | 0.380222 | 0.420 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.552629 | 0.258 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.229286 | 0.640 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.229286 | 0.640 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.317248 | 0.499 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.199564 | 0.700 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.587570 | 0.231 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.225894 | 0.646 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.315319 | 0.501 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.513343 | 0.290 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 0.081586 | 1.088 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 0.193836 | 0.713 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.266915 | 0.574 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 0.340550 | 0.468 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 0.453637 | 0.343 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.219238 | 0.659 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.320129 | 0.495 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.402702 | 0.395 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.553365 | 0.257 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.535551 | 0.271 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.634898 | 0.197 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.396824 | 0.401 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.293148 | 0.533 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.103089 | 0.987 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.145551 | 0.837 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.312557 | 0.505 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.600523 | 0.221 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.583525 | 0.234 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.213715 | 0.670 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.265945 | 0.575 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.355049 | 0.450 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.511617 | 0.291 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.541407 | 0.266 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.071531 | 1.146 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.312557 | 0.505 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.572993 | 0.242 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.577554 | 0.238 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 0.603925 | 0.219 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.558178 | 0.253 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.083963 | 1.076 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.203959 | 0.690 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.598082 | 0.223 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.624479 | 0.204 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.153066 | 0.815 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.160065 | 0.796 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.581991 | 0.235 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.125102 | 0.903 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.205580 | 0.687 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.443315 | 0.353 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.203572 | 0.691 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.572993 | 0.242 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.572993 | 0.242 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 0.157552 | 0.803 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 0.266915 | 0.574 | 0 | 0 |
| SLC-mediated transport of oligopeptides | R-HSA-9959399 | 0.266915 | 0.574 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.219600 | 0.658 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 0.453637 | 0.343 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 0.453637 | 0.343 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.186153 | 0.730 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 0.411735 | 0.385 | 0 | 0 |
| Inositol transporters | R-HSA-429593 | 0.506010 | 0.296 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 0.506010 | 0.296 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.132847 | 0.877 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.357148 | 0.447 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 0.553365 | 0.257 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.486427 | 0.313 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.486427 | 0.313 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.541178 | 0.267 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 0.596183 | 0.225 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 0.596183 | 0.225 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 0.634898 | 0.197 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.624479 | 0.204 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.624479 | 0.204 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.624479 | 0.204 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.622314 | 0.206 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.467402 | 0.330 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.511887 | 0.291 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.201906 | 0.695 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.608289 | 0.216 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.445489 | 0.351 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.500391 | 0.301 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.416160 | 0.381 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.330909 | 0.480 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.340550 | 0.468 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 0.553365 | 0.257 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.559087 | 0.253 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.194935 | 0.710 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.235291 | 0.628 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.411735 | 0.385 | 0 | 0 |
| Zinc efflux and compartmentalization by the SLC30 family | R-HSA-435368 | 0.506010 | 0.296 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.378812 | 0.422 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.552629 | 0.258 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.115297 | 0.938 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.355049 | 0.450 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.615517 | 0.211 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.171494 | 0.766 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.526606 | 0.279 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.460941 | 0.336 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.336096 | 0.474 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.310460 | 0.508 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.435679 | 0.361 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 0.299994 | 0.523 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.400712 | 0.397 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.490477 | 0.309 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.319270 | 0.496 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 0.331659 | 0.479 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.073074 | 1.136 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.272855 | 0.564 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.327259 | 0.485 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.290185 | 0.537 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 0.506010 | 0.296 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.201747 | 0.695 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.337436 | 0.472 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.337436 | 0.472 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.355049 | 0.450 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 0.553365 | 0.257 | 0 | 0 |
| Relaxin receptors | R-HSA-444821 | 0.553365 | 0.257 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 0.553365 | 0.257 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 0.596183 | 0.225 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.493189 | 0.307 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.448490 | 0.348 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 0.598082 | 0.223 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.634898 | 0.197 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.326437 | 0.486 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.525480 | 0.279 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.596571 | 0.224 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.450062 | 0.347 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.566139 | 0.247 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.585413 | 0.233 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.604723 | 0.218 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.603925 | 0.219 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.415586 | 0.381 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.092131 | 1.036 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.593789 | 0.226 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 0.246001 | 0.609 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.335075 | 0.475 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.337457 | 0.472 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 0.246001 | 0.609 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.299994 | 0.523 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 0.376564 | 0.424 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.290185 | 0.537 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 0.411735 | 0.385 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.506010 | 0.296 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.302553 | 0.519 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 0.553365 | 0.257 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 0.553365 | 0.257 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 0.553365 | 0.257 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.460765 | 0.337 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.511316 | 0.291 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 0.596183 | 0.225 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 0.596183 | 0.225 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.559087 | 0.253 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 0.634898 | 0.197 | 0 | 0 |
| CREB3 factors activate genes | R-HSA-8874211 | 0.596183 | 0.225 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 0.570314 | 0.244 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.465175 | 0.332 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 0.279267 | 0.554 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.583525 | 0.234 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.376564 | 0.424 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.411735 | 0.385 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.402702 | 0.395 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.105535 | 0.977 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 0.506010 | 0.296 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.434922 | 0.362 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 0.553365 | 0.257 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.313596 | 0.504 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.484446 | 0.315 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 0.634898 | 0.197 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.363818 | 0.439 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.579821 | 0.237 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.159287 | 0.798 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 0.624479 | 0.204 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.124367 | 0.905 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 0.203959 | 0.690 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 0.312557 | 0.505 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.635559 | 0.197 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.641420 | 0.193 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.643095 | 0.192 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.644176 | 0.191 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.645636 | 0.190 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.645636 | 0.190 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.645636 | 0.190 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.645636 | 0.190 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.645636 | 0.190 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.645636 | 0.190 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 0.645636 | 0.190 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 0.645636 | 0.190 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 0.649510 | 0.187 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.649510 | 0.187 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.649510 | 0.187 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.649510 | 0.187 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.649510 | 0.187 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.651033 | 0.186 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.652124 | 0.186 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.652124 | 0.186 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.652124 | 0.186 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.652570 | 0.185 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.657200 | 0.182 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.657960 | 0.182 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.657960 | 0.182 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.657960 | 0.182 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.662651 | 0.179 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.662651 | 0.179 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.663215 | 0.178 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.664407 | 0.178 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 0.665289 | 0.177 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.665289 | 0.177 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.665289 | 0.177 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.665289 | 0.177 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.665289 | 0.177 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.665289 | 0.177 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.665289 | 0.177 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.666549 | 0.176 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.669379 | 0.174 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.669379 | 0.174 | 0 | 0 |
| ALKBH3 mediated reversal of alkylation damage | R-HSA-112126 | 0.669904 | 0.174 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 0.669904 | 0.174 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 0.669904 | 0.174 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 0.669904 | 0.174 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.669904 | 0.174 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 0.669904 | 0.174 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 0.669904 | 0.174 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 0.669904 | 0.174 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 0.669904 | 0.174 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 0.669904 | 0.174 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 0.669904 | 0.174 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 0.669904 | 0.174 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.669904 | 0.174 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.672996 | 0.172 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 0.673196 | 0.172 | 0 | 0 |
| PKA activation | R-HSA-163615 | 0.673196 | 0.172 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 0.673196 | 0.172 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.673196 | 0.172 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.673196 | 0.172 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 0.673196 | 0.172 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 0.673196 | 0.172 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.673196 | 0.172 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.673196 | 0.172 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.676018 | 0.170 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.679560 | 0.168 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.680089 | 0.167 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.680089 | 0.167 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.680168 | 0.167 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.680168 | 0.167 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.681989 | 0.166 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 0.684134 | 0.165 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.684134 | 0.165 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.684134 | 0.165 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.684134 | 0.165 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.684134 | 0.165 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.686763 | 0.163 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.686763 | 0.163 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.693420 | 0.159 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.694290 | 0.158 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.694290 | 0.158 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.695564 | 0.158 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.695564 | 0.158 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 0.695564 | 0.158 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.695564 | 0.158 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 0.695564 | 0.158 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.695564 | 0.158 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.696052 | 0.157 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.696052 | 0.157 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.696052 | 0.157 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.697465 | 0.156 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.700325 | 0.155 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.700325 | 0.155 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 0.701555 | 0.154 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 0.701555 | 0.154 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 0.701555 | 0.154 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.701555 | 0.154 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 0.701555 | 0.154 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 0.701555 | 0.154 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 0.701555 | 0.154 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.701555 | 0.154 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 0.701555 | 0.154 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.701555 | 0.154 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 0.701555 | 0.154 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 0.701555 | 0.154 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.701555 | 0.154 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.701555 | 0.154 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 0.701555 | 0.154 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.702176 | 0.154 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.702176 | 0.154 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.705609 | 0.151 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.707710 | 0.150 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.711108 | 0.148 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.711436 | 0.148 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.714765 | 0.146 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.714765 | 0.146 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 0.716649 | 0.145 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.717950 | 0.144 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.718099 | 0.144 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.719420 | 0.143 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.719420 | 0.143 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.720229 | 0.143 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.721239 | 0.142 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.721239 | 0.142 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.726242 | 0.139 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 0.726242 | 0.139 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.726242 | 0.139 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.726242 | 0.139 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.727495 | 0.138 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.729050 | 0.137 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.729304 | 0.137 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 0.730173 | 0.137 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 0.730173 | 0.137 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.730173 | 0.137 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 0.730173 | 0.137 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 0.730173 | 0.137 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 0.730173 | 0.137 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 0.730173 | 0.137 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 0.730173 | 0.137 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.730173 | 0.137 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 0.730173 | 0.137 | 0 | 0 |
| Serotonin receptors | R-HSA-390666 | 0.730173 | 0.137 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 0.730173 | 0.137 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.734315 | 0.134 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.735878 | 0.133 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.736492 | 0.133 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.736492 | 0.133 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 0.736492 | 0.133 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 0.736492 | 0.133 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 0.736492 | 0.133 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 0.736492 | 0.133 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.736492 | 0.133 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.736492 | 0.133 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.736492 | 0.133 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.740033 | 0.131 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 0.740475 | 0.130 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 0.740475 | 0.130 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 0.740475 | 0.130 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.740647 | 0.130 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.742172 | 0.129 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.742717 | 0.129 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.748553 | 0.126 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.749339 | 0.125 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.749565 | 0.125 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.751054 | 0.124 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.751562 | 0.124 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 0.751562 | 0.124 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.754138 | 0.123 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.754138 | 0.123 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.754138 | 0.123 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.755136 | 0.122 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.755136 | 0.122 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 0.755136 | 0.122 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.755136 | 0.122 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.755136 | 0.122 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.755136 | 0.122 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.756048 | 0.121 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 0.756048 | 0.121 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 0.756048 | 0.121 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 0.756048 | 0.121 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 0.756048 | 0.121 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 0.756048 | 0.121 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 0.756048 | 0.121 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.756048 | 0.121 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 0.756048 | 0.121 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 0.756048 | 0.121 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.759112 | 0.120 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.765110 | 0.116 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.766489 | 0.115 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.766489 | 0.115 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.766489 | 0.115 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 0.766489 | 0.115 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.767066 | 0.115 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.772214 | 0.112 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 0.772629 | 0.112 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.772629 | 0.112 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.772629 | 0.112 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.775755 | 0.110 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 0.779444 | 0.108 | 0 | 0 |
| Endosomal/Vacuolar pathway | R-HSA-1236977 | 0.779444 | 0.108 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 0.779444 | 0.108 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 0.779444 | 0.108 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 0.779444 | 0.108 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 0.779444 | 0.108 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 0.779444 | 0.108 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 0.779444 | 0.108 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.779790 | 0.108 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 0.779790 | 0.108 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.780676 | 0.108 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 0.780676 | 0.108 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 0.780676 | 0.108 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.780676 | 0.108 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.781290 | 0.107 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.781290 | 0.107 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.781290 | 0.107 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.785437 | 0.105 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 0.789021 | 0.103 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 0.789021 | 0.103 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 0.789021 | 0.103 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 0.789021 | 0.103 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.789021 | 0.103 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.789021 | 0.103 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.789021 | 0.103 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.789758 | 0.103 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.790578 | 0.102 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.791796 | 0.101 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.791796 | 0.101 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.792979 | 0.101 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.795949 | 0.099 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.795949 | 0.099 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.795949 | 0.099 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.796211 | 0.099 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.796377 | 0.099 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 0.800597 | 0.097 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 0.800597 | 0.097 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 0.800597 | 0.097 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 0.800597 | 0.097 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 0.800597 | 0.097 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.800597 | 0.097 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 0.800597 | 0.097 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 0.800597 | 0.097 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 0.800597 | 0.097 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.800597 | 0.097 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 0.800597 | 0.097 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.800597 | 0.097 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.800597 | 0.097 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.800597 | 0.097 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 0.800597 | 0.097 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 0.800597 | 0.097 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 0.800597 | 0.097 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 0.800597 | 0.097 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.801133 | 0.096 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.802186 | 0.096 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.803272 | 0.095 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.804323 | 0.095 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.804323 | 0.095 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.804361 | 0.095 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 0.804361 | 0.095 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.804361 | 0.095 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.804361 | 0.095 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.804361 | 0.095 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.804361 | 0.095 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.804361 | 0.095 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 0.804361 | 0.095 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 0.804361 | 0.095 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 0.804361 | 0.095 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.806916 | 0.093 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.806916 | 0.093 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.806916 | 0.093 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.806916 | 0.093 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 0.806916 | 0.093 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.808541 | 0.092 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.813408 | 0.090 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.814228 | 0.089 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 0.814228 | 0.089 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.814713 | 0.089 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.816712 | 0.088 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 0.818701 | 0.087 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.818701 | 0.087 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 0.818701 | 0.087 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 0.818701 | 0.087 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.819012 | 0.087 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 0.819722 | 0.086 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.819722 | 0.086 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.819722 | 0.086 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 0.819722 | 0.086 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 0.819722 | 0.086 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 0.819722 | 0.086 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 0.819722 | 0.086 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 0.819722 | 0.086 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 0.819722 | 0.086 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 0.819722 | 0.086 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.823000 | 0.085 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.823000 | 0.085 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.824679 | 0.084 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.824679 | 0.084 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.824679 | 0.084 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.824679 | 0.084 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.824679 | 0.084 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.825463 | 0.083 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.829574 | 0.081 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.832091 | 0.080 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 0.832091 | 0.080 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 0.832091 | 0.080 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.832091 | 0.080 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.832091 | 0.080 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.832091 | 0.080 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 0.832091 | 0.080 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.832191 | 0.080 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.834638 | 0.079 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 0.837014 | 0.077 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.837014 | 0.077 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 0.837014 | 0.077 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 0.837014 | 0.077 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 0.837014 | 0.077 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 0.837014 | 0.077 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 0.837014 | 0.077 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 0.837014 | 0.077 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.837014 | 0.077 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 0.837014 | 0.077 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 0.837014 | 0.077 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.840344 | 0.076 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.840988 | 0.075 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.841275 | 0.075 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.841298 | 0.075 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.842273 | 0.075 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.842747 | 0.074 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.842815 | 0.074 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.844120 | 0.074 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.844582 | 0.073 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.844582 | 0.073 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.844582 | 0.073 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.849402 | 0.071 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.849665 | 0.071 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.849886 | 0.071 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.851490 | 0.070 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.851490 | 0.070 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.851490 | 0.070 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.851490 | 0.070 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.851490 | 0.070 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.851490 | 0.070 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.852649 | 0.069 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 0.852649 | 0.069 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.852649 | 0.069 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 0.852649 | 0.069 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 0.852649 | 0.069 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.852649 | 0.069 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.852649 | 0.069 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 0.852649 | 0.069 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 0.852649 | 0.069 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.852649 | 0.069 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.852649 | 0.069 | 0 | 0 |
| Dopamine clearance from the synaptic cleft | R-HSA-379401 | 0.852649 | 0.069 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 0.852649 | 0.069 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 0.852649 | 0.069 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.852649 | 0.069 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.853140 | 0.069 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.853140 | 0.069 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.856222 | 0.067 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.856222 | 0.067 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.856338 | 0.067 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.859742 | 0.066 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.861127 | 0.065 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.861127 | 0.065 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.862771 | 0.064 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.863284 | 0.064 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.863957 | 0.064 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 0.866784 | 0.062 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 0.866784 | 0.062 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 0.866784 | 0.062 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 0.866784 | 0.062 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 0.866784 | 0.062 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 0.866784 | 0.062 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.866784 | 0.062 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.866784 | 0.062 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 0.866784 | 0.062 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 0.866784 | 0.062 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.867060 | 0.062 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.867060 | 0.062 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.867060 | 0.062 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 0.867060 | 0.062 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.867060 | 0.062 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 0.870209 | 0.060 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.874935 | 0.058 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.877143 | 0.057 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.877143 | 0.057 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.877143 | 0.057 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.877143 | 0.057 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.877143 | 0.057 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 0.877143 | 0.057 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 0.877143 | 0.057 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 0.877143 | 0.057 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.877577 | 0.057 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.878763 | 0.056 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.879438 | 0.056 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.879438 | 0.056 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 0.879564 | 0.056 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 0.879564 | 0.056 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 0.879564 | 0.056 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 0.879564 | 0.056 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 0.879564 | 0.056 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.879564 | 0.056 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 0.879564 | 0.056 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.880656 | 0.055 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.882824 | 0.054 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.884901 | 0.053 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 0.886516 | 0.052 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.886516 | 0.052 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.886516 | 0.052 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.886949 | 0.052 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 0.891119 | 0.050 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 0.891119 | 0.050 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 0.891119 | 0.050 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 0.891119 | 0.050 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 0.891119 | 0.050 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.891119 | 0.050 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.891119 | 0.050 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.891119 | 0.050 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.891119 | 0.050 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 0.891119 | 0.050 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.891508 | 0.050 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.893218 | 0.049 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.894380 | 0.048 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.894380 | 0.048 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.894380 | 0.048 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.895222 | 0.048 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.898409 | 0.047 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.898471 | 0.046 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.898471 | 0.046 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.898471 | 0.046 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.900236 | 0.046 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.901279 | 0.045 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 0.901490 | 0.045 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.901490 | 0.045 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.901566 | 0.045 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 0.901566 | 0.045 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 0.901566 | 0.045 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.901566 | 0.045 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.901566 | 0.045 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.902823 | 0.044 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 0.903302 | 0.044 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 0.903302 | 0.044 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.903302 | 0.044 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.903302 | 0.044 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.906205 | 0.043 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.906786 | 0.042 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.908165 | 0.042 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.908165 | 0.042 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.908165 | 0.042 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.908165 | 0.042 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.909466 | 0.041 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 0.910500 | 0.041 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.910798 | 0.041 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 0.910798 | 0.041 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 0.910798 | 0.041 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 0.911011 | 0.040 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 0.911011 | 0.040 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 0.911011 | 0.040 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.911011 | 0.040 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 0.911011 | 0.040 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 0.911011 | 0.040 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.912625 | 0.040 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.913909 | 0.039 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.914427 | 0.039 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.916052 | 0.038 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.917746 | 0.037 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 0.917746 | 0.037 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.917746 | 0.037 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.917746 | 0.037 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.917746 | 0.037 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.917746 | 0.037 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.917746 | 0.037 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 0.917746 | 0.037 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 0.919550 | 0.036 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 0.919550 | 0.036 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 0.919550 | 0.036 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.919550 | 0.036 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 0.919550 | 0.036 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 0.919550 | 0.036 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 0.919550 | 0.036 | 0 | 0 |
| Keratan sulfate degradation | R-HSA-2022857 | 0.919550 | 0.036 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 0.919550 | 0.036 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 0.919550 | 0.036 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.920298 | 0.036 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 0.920298 | 0.036 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.921294 | 0.036 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.921294 | 0.036 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.923143 | 0.035 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.924182 | 0.034 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.924182 | 0.034 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 0.924182 | 0.034 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 0.924182 | 0.034 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.925299 | 0.034 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.927270 | 0.033 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.930141 | 0.031 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.930141 | 0.031 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.930141 | 0.031 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.930141 | 0.031 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.930141 | 0.031 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.930418 | 0.031 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.931636 | 0.031 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.932431 | 0.030 | 0 | 0 |
| CS-GAG biosynthesis | R-HSA-2022870 | 0.934250 | 0.030 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 0.934250 | 0.030 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 0.934250 | 0.030 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 0.934250 | 0.030 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 0.934250 | 0.030 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 0.934250 | 0.030 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.935177 | 0.029 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.935300 | 0.029 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.935647 | 0.029 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 0.935655 | 0.029 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.935655 | 0.029 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 0.935655 | 0.029 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.936188 | 0.029 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.940275 | 0.027 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.940546 | 0.027 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.940561 | 0.027 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.940561 | 0.027 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.940561 | 0.027 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 0.940561 | 0.027 | 0 | 0 |
| Reactions specific to the complex N-glycan synthesis pathway | R-HSA-975578 | 0.940561 | 0.027 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 0.940561 | 0.027 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.940561 | 0.027 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.940561 | 0.027 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.943339 | 0.025 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 0.943339 | 0.025 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.943959 | 0.025 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.946172 | 0.024 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 0.946266 | 0.024 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 0.946266 | 0.024 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 0.946266 | 0.024 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 0.946266 | 0.024 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.947334 | 0.023 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.947663 | 0.023 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.948422 | 0.023 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.948422 | 0.023 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.949824 | 0.022 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 0.949824 | 0.022 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 0.949824 | 0.022 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.949824 | 0.022 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.949912 | 0.022 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.949956 | 0.022 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.950455 | 0.022 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 0.951424 | 0.022 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 0.951424 | 0.022 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 0.951424 | 0.022 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.951424 | 0.022 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.951424 | 0.022 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 0.952096 | 0.021 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.953846 | 0.021 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.955524 | 0.020 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.955524 | 0.020 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.955524 | 0.020 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 0.956086 | 0.020 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.956086 | 0.020 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.956086 | 0.020 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 0.956086 | 0.020 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 0.956086 | 0.020 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 0.956086 | 0.020 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.956342 | 0.019 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.956604 | 0.019 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.956904 | 0.019 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.957558 | 0.019 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.957558 | 0.019 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 0.957558 | 0.019 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 0.960302 | 0.018 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 0.960302 | 0.018 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 0.960302 | 0.018 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.960523 | 0.017 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.960867 | 0.017 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.960984 | 0.017 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 0.960984 | 0.017 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 0.960984 | 0.017 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.961702 | 0.017 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.962284 | 0.017 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.962470 | 0.017 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.963341 | 0.016 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 0.964113 | 0.016 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 0.964113 | 0.016 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 0.964113 | 0.016 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.964113 | 0.016 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 0.964113 | 0.016 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 0.964113 | 0.016 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.964480 | 0.016 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.964801 | 0.016 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.965732 | 0.015 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.965732 | 0.015 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.966691 | 0.015 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.966691 | 0.015 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.967055 | 0.015 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.967055 | 0.015 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 0.967055 | 0.015 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 0.967067 | 0.015 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.967067 | 0.015 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.967559 | 0.014 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 0.967559 | 0.014 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 0.967559 | 0.014 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.969373 | 0.014 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 0.969475 | 0.013 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.969475 | 0.013 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.969475 | 0.013 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.969739 | 0.013 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.969739 | 0.013 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.970317 | 0.013 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.970565 | 0.013 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 0.970674 | 0.013 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.971445 | 0.013 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.971716 | 0.012 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.972211 | 0.012 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.972211 | 0.012 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.973385 | 0.012 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 0.973490 | 0.012 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.974356 | 0.011 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.974443 | 0.011 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.974488 | 0.011 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.975664 | 0.011 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.975844 | 0.011 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.975920 | 0.011 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.975920 | 0.011 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.976035 | 0.011 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 0.976035 | 0.011 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 0.976035 | 0.011 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.977454 | 0.010 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.977540 | 0.010 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 0.978337 | 0.010 | 0 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 0.978337 | 0.010 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 0.978513 | 0.009 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 0.978513 | 0.009 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.979817 | 0.009 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.980230 | 0.009 | 0 | 0 |
| Keratan sulfate biosynthesis | R-HSA-2022854 | 0.980417 | 0.009 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.980417 | 0.009 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.981061 | 0.008 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.981061 | 0.008 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.981518 | 0.008 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.981677 | 0.008 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.981920 | 0.008 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.982198 | 0.008 | 0 | 0 |
| CS/DS degradation | R-HSA-2024101 | 0.982298 | 0.008 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 0.982298 | 0.008 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.983420 | 0.007 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.983420 | 0.007 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.983420 | 0.007 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.983713 | 0.007 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 0.983998 | 0.007 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.983998 | 0.007 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 0.983998 | 0.007 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 0.983998 | 0.007 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 0.983998 | 0.007 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.984799 | 0.007 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.985535 | 0.006 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.985943 | 0.006 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 0.985943 | 0.006 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.986066 | 0.006 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 0.986066 | 0.006 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.986278 | 0.006 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.986919 | 0.006 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 0.986925 | 0.006 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.986925 | 0.006 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.987043 | 0.006 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.987201 | 0.006 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.987231 | 0.006 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.987734 | 0.005 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.987734 | 0.005 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.987961 | 0.005 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.988181 | 0.005 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 0.988181 | 0.005 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 0.988181 | 0.005 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 0.988181 | 0.005 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.988181 | 0.005 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.988817 | 0.005 | 0 | 0 |
| Depurination | R-HSA-73927 | 0.989316 | 0.005 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 0.989316 | 0.005 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 0.989316 | 0.005 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 0.989316 | 0.005 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 0.989316 | 0.005 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.989592 | 0.005 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.989614 | 0.005 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 0.989614 | 0.005 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 0.990343 | 0.004 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.990343 | 0.004 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.990357 | 0.004 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.990915 | 0.004 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.991010 | 0.004 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.991010 | 0.004 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.991049 | 0.004 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.991271 | 0.004 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.991271 | 0.004 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 0.991271 | 0.004 | 0 | 0 |
| N-glycan antennae elongation in the medial/trans-Golgi | R-HSA-975576 | 0.991271 | 0.004 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.991353 | 0.004 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.991694 | 0.004 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.991725 | 0.004 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.992109 | 0.003 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 0.992109 | 0.003 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 0.992109 | 0.003 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.992293 | 0.003 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.992411 | 0.003 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 0.992464 | 0.003 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.992485 | 0.003 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.992852 | 0.003 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.992868 | 0.003 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 0.992868 | 0.003 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 0.992868 | 0.003 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.993103 | 0.003 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.993345 | 0.003 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.993828 | 0.003 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.993854 | 0.003 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.993983 | 0.003 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 0.994303 | 0.002 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 0.994733 | 0.002 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.994733 | 0.002 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.995167 | 0.002 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.995239 | 0.002 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.995239 | 0.002 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.995342 | 0.002 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 0.995580 | 0.002 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.995617 | 0.002 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.995617 | 0.002 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.995617 | 0.002 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.995697 | 0.002 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.995803 | 0.002 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 0.996110 | 0.002 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 0.996110 | 0.002 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 0.996110 | 0.002 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.996134 | 0.002 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.996340 | 0.002 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.996442 | 0.002 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 0.996484 | 0.002 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.996484 | 0.002 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.996669 | 0.001 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.996686 | 0.001 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.996763 | 0.001 | 0 | 0 |
| Keratan sulfate/keratin metabolism | R-HSA-1638074 | 0.996822 | 0.001 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.996822 | 0.001 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.996906 | 0.001 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.996912 | 0.001 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.996915 | 0.001 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.996915 | 0.001 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.997128 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 0.997128 | 0.001 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.997404 | 0.001 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 0.997404 | 0.001 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.997404 | 0.001 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.997601 | 0.001 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.997646 | 0.001 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 0.997758 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 0.997847 | 0.001 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.997847 | 0.001 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.997879 | 0.001 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 0.997879 | 0.001 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.997913 | 0.001 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.998071 | 0.001 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.998117 | 0.001 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.998170 | 0.001 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.998177 | 0.001 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.998177 | 0.001 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 0.998268 | 0.001 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.998298 | 0.001 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.998352 | 0.001 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.998359 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 0.998359 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.998359 | 0.001 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.998434 | 0.001 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.998453 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.998478 | 0.001 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 0.998502 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 0.998585 | 0.001 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.998585 | 0.001 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.998682 | 0.001 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.998757 | 0.001 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 0.998799 | 0.001 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 0.998844 | 0.001 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 0.998955 | 0.000 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.998959 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 0.999215 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.999223 | 0.000 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.999433 | 0.000 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.999484 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.999485 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 0.999535 | 0.000 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.999535 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.999567 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 0.999569 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 0.999620 | 0.000 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.999621 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.999657 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.999657 | 0.000 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 0.999690 | 0.000 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.999690 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 0.999690 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.999701 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 0.999720 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 0.999747 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.999782 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.999819 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 0.999819 | 0.000 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.999831 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 0.999831 | 0.000 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.999836 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.999858 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.999859 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 0.999868 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.999875 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 0.999878 | 0.000 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.999899 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 0.999908 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.999944 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 0.999952 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 0.999953 | 0.000 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.999970 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.999973 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.999973 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.999973 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 0.999976 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.999980 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.999990 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 0.999990 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 0.999991 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.999996 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 0.999997 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 0.999997 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.999998 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 0.999998 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.999999 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 0.999999 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 0.999999 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 0.999999 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.000000 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |